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ABSTRACT


Ryan, Valerie E. M.S., Purdue University, December 2016. Recombinant Listeria
Adhesion Protein Expressing Probiotics Protect Against Listeria monocytogenes
Infection in Animal Models. Major Professor: Arun Bhunia.

Listeria monocytogenes (Lm) is a foodborne pathogen, found ubiquitously in nature, and
has a high morbidity rate among immunocompromised individuals, the elderly, and
especially pregnant women and their fetuses resulting in abortion, stillbirth, and neonatal
infection. There are currently no preventative medical interventions against Lm
infection. The Listeria adhesion protein (LAP) is present in both pathogenic and nonpathogenic Listeria (i.e., L. innocua) and has shown to interact with host epithelial
proteins causing tight junction dysregulation aiding in pathogen attachment and
paracellular translocation across the host intestinal epithelium. Our lab has demonstrated
that recombinant probiotics, Lactobacillus casei (LbcWT) expressing LAP from either
the pathogenic L. monocytogenes (LbcLAPLm) or the nonpathogenic L. innocua
(LbcLAPLin) prevented Lm attachment in in vitro cell culture experiments. Here, we
investigated the beneficial attributes of our recombinant probiotics against clinical
listerial infection of healthy mice and subclinical listerial infection in pregnant guinea
pigs (GP). We supplied animals with freshly prepared wild type (LbcWT) and
recombinant probiotics (9  109 cfu/ml) in sterile water daily for 10 (mice) or 17 days
(GP). They were challenged with a clinical dose (4  108 cfu/mouse) and subclinical
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dose (9  108 or 4.5  109 cfu/GP) of Lm and sacrificed 48 h (mice) or 72 h (GP) post
challenge. Organs, tissues, blood, feces and fetuses were collected for Lm presence and
enumeration. Also, probiotic colonization, short chain fatty acid (SCFA), and serum
cytokine, cholesterol, and trace mineral profiles were determined. Histopathological
samples from the ileum, liver, and mesenteric lymph nodes (MLN) were scored for
inflammation. Recombinant probiotics reduced Lm carriage in the challenged mice 3-5
log. In the recombinant probiotic-fed GP groups, Lm was present in the maternal liver,
spleen, and MLN and absent in the maternal blood, kidney, placenta, and fetal liver,
while LbcWT and Lm control groups showed Lm presence in nearly all tissues tested.
We found no probiotic bacteria in any extra-intestinal tissues. Recombinant probiotic-fed
groups showed a decrease in pro-inflammatory cytokines (TNF, IL-6, TGF) in contrast
to LbcWT and Lm control groups. Total SCFA content suggests that probiotics helped
maintain SCFA levels against the detrimental effects of Lm. Among the trace minerals
tested, serum calcium and zinc levels were higher (P < 0.05) in recombinant probiotic-fed
groups than the LbcWT and Lm control groups. Taken together, these data indicate that
LAP-expressing recombinant probiotics confer anti-listerial effects, participate in
immune modulation and have a positive impact on overall health in mice and pregnant
of the population, these recombinant probiotics could confer protection against Lm and
provide a platform for future research into the use of probiotics as a “probiotic vaccine.”
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CHAPTER 1. INTRODUCTION

1.1. Foodborne Pathogens and Disease
Enteric foodborne pathogens continue to be an increasingly severe global health
concern. While the total global burden of foodborne illness is very difficult to
investigate, in the year 2010, the World Health Organization (WHO) estimated that 22
foodborne pathogens were responsible for approximately 2 billion illnesses, resulting in
over 1 million deaths The Centers for Disease Control and Prevention (CDC) estimated
that, in the United States alone, approximately 48 million cases of foodborne disease
occur annually, resulting in 128,000 hospitalizations and 3,000 deaths (Scallan et al.
2011). Foodborne illness outbreak data from 2006 to 2010 revealed that bacterial
pathogens were responsible for 40% of the outbreaks, norovirus for 49%, chemicals 6%,
parasites 1%, and other multiple miscellaneous agents were responsible for 4% when
etiologic agents were known. There are many bacterial, viral, fungal, and parasitic
adulterants in the global food supply; however, to be of particular concern to cause
illness, agents must have the potential to cause significant morbidity and mortality with a
relatively low infective dose, be ubiquitous in nature, and be able to persist or multiply in
food. According to WHO, the major foodborne enteric pathogens include nontyphoidal
Salmonella, Campylobacter, Shiga-Toxin Producing E. coli (STEC), Listeria, Vibrio and
Norovirus. Among the foodborne diseases, the gastrointestinal disorders are most
predominant resulting in abdominal cramp, nausea, vomiting, diarrhea and dysentery.
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The disease is caused primarily by Staphylococcus aureus, Bacillus cereus, Cronobacter
sakazaki, Salmonella enterica, Shigella spp, Vibrio spp, Norovirus, Ebola virus,
Rotavirus, Entamoeba histolytica, Cryptosporidium, Cyclospora, Giardia, Isospora,
Taenia spp. and many more. In addition, foodborne pathogens may cause reactive
arthritis, Reiter’s syndrome, and rheumatoid arthritis, as sequelae to Campylobacter,
Salmonella, Shigella, and Yersinia infections. Debilitating Guillain Barre Syndrome
(GBS) can also follow after Campylobacter infection. Hemorrhagic uremic syndrome
(HUS) and kidney damage can happen due to Shiga toxins produced by STEC and
Shigella spp. Hepatitis and jaundice are caused by food and waterborne Hepatitis A virus
(HAV) and Hepatitis E virus (HEV) infections. Pregnancy related complications,
miscarriage, and stillbirth, neonatal and perinatal infections are due to Listeria
monocytogenes and Toxoplasma gondii infections. Central nervous system disorder,
meningitis and menigoencephalitis can be caused by Listeria monocytogenes, bovine
spongiform encephalopathy (BSE), and Nipha virus. Neurological disorders and paralysis
may result from consumption of toxins produced by Clostridium botulinum and seafood
toxins, and from Campylobacter infection. Acute or chronic disease including
malignancies and auto-immune diseases may result from mycotoxin exposures, and
allergic responses by seafood toxins such as histamine, saurine cadaverine and other
small amines.
Over the last few decades, our understanding of the relationship between the diet
and general health has evolved from the simplistic perception of primarily only an
acquisition of nutrients needed for metabolism to a greater understanding of how specific
foods promote the overall well-being of an individual (e.g., “superfoods,” antioxidants,
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anti-inflammatories, etc.). This understanding fostered the use of the term “functional
foods.” Foods that, beyond simply providing nutritional value, can benefit additional
specific functions within the body, are considered functional foods (Figueroa-Gonzalez et
al. 2011). Because of their ability to specifically enhance gut health and function,
probiotics may be considered a functional food (Nagpal et al. 2012). Probiotics are
typically nonpathogenic microorganisms that promote health benefits when administered
in clinically-appropriate dosing. The most common probiotics are Lactobacillus and
Bifidobacterium. To be considered a probiotic, a microorganism must exert benefits in
three ways: (i) Provide the host with organic acids (short chain fatty acids) through
anaerobic fermentation of carbohydrates that can be positively utilized by the host. There
has been a wealth of recent studies investigating the wide reach of these fermentation end
products, suggesting that they play a major role in brain function and cognition. (ii)
Stimulate or prime the host immune system, without causing inflammation within the
gastrointestinal tract (GIT). (iii) Exclude pathogens in the GIT from causing disease by
outcompeting them for the limited resources and space (Stecher and Hardt 2011). In
general, probiotics are known to prevent/alleviate chronic inflammatory bowel disease,
colorectal cancer, metabolic disorders, allergic response, obesity, and osteoporosis
(Azcarate-Peril et al. 2011; Ly et al. 2011; Amalaradjou and Bhunia 2012; Cate et al.
2015; Kim et al. 2016). They are also administered in preterm neonates to allow early
colonization of beneficial microorganisms (Deshpande et al. 2011)
Further, probiotics must be administered in adequate amounts to be beneficial.
Widespread colonization of the gut by probiotics can obstruct pathogen access to the
physical niche required for attachment and infection (Gaggia et al. 2010). If physical
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displacement is insufficient and a pathogen is able to colonize, probiotics have several
functional attributes which allow them to effectively subvert pathogen infections within
the gut. Like many microorganisms trying to survive within a complex ecosystem,
several probiotics can inactivate pathogens through the secretion of antimicrobial
peptides, called bacteriocins (Klaenhammer 1993; Amalaradjou and Bhunia 2012). As
previously stated, probiotics stimulate the host immune system, allowing for a prompt
host immune response to host-pathogen interaction (Oelschlaeger 2010; Gourbeyre et al.
2011). While probiotics appear to be a good candidate to confer protection against
enteric pathogens, the efficacy of probiotics is often unpredictable and strain specific.
Using probiotic mitigation of enteric pathogens as a template, while addressing the
short comings of unpredictability and strain specificity out lab has bioengineered a
recombinant Lactobacillus casei expressing the Listeria Adhesion Protein (LAP) from both
pathogenic Listeria monocytogenes (LbcLAPLm) and non-pathogenic Listeria innocua
(LbcLAPLin). We have demonstrated the ability of these recombinant probiotics to reduce
adhesion, invasion, and translocation of L. monocytogenes in vitro (Koo et al 2012;
Amalardjou et al., in preparation) and their protection against infection in mice. Here we
seek to further investigate the efficacy of these probiotics in vivo. In this thesis we will
confirm that the recombinant probiotics expressing LAP, especially from L. innocua,
confer protection against clinical L. monocytogenes infection in mice. Further, we will
show that they also protect against infection in pregnant guinea pigs. We will investigate
the mechanisms that the probiotics employ to mitigate infection and other general health
benefits these probiotics bestow in the host.
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CHAPTER 2. LITERATURE REVIEW
2.1. Listeria monocytogenes – Foodborne Pathogen
The genus Listeria was termed by Pirie in 1940 to represent all catalase positive,
Gram-positive rods (Pirie 1940). There are currently 17 known species of Listeria, which
are broken into two groups based on genotypic and phenotypic similarities: (i) Listeria
sensu strictu, L. monocytogenes, L. seeligeri, L. marthii, L. ivanovii, L. welshimeri, and L.
innocua, and (ii) Listeria sensu lato (discovered after 2009), L. grayi, L. rocourtiae, L.
weihenstephanensis, L. grandensis, L. riparia, L. booriae, L. fleischmannii, L.
floridensis, L. aquatica, L. newyorkensis, and L. cornellensis (Orsi et al. 2011; Orsi and
Wiedmann 2016) Of these species, only two are pathogens, L. ivanovii and L.
monocytogenes. L. ivanovii is an animal pathogen that is particularly important in
ruminants, while L. monocytogenes is a human pathogen that causes a third of foodborne
deaths (Scallan et al. 2011). The health and economic burden related to outbreaks and
food recalls are high societally and in the food industry (Ivanek et al. 2004).
Listeria monocytogenes was first described by E.D.G Murray in 1926 and
originally named Bacterium monocytogenes; however, when Pirie named the genus of
catalase positive, gram-positive rods Listeria in 1940, it was reclassified as Listeria
monocytogenes. In a natural environment, L. monocytogenes adopts a saprophytic
lifestyle; however, within mammalian hosts, a set of inducible virulence factors allows
for establishment of productive infection. L. monocytogenes can be broken down into 13
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different serotypes, with serotypes 1/2a, 1/2b, and 4b cause 96% of human infection;
however, serotype 4b is associated with the majority of listeriosis outbreaks. This may be
due to its higher mobility (Swaminathan and Gerner-Smidt 2007).
L. monocytogenes is also grouped into lineages which are based on their ribotype
patter and virulence genes (Bhunia 2007). Lineage I has the highest virulence and is
associated with most Listeria outbreaks. Lineage II is the intermediate group associated
with sporadic outbreaks, while lineage III is not associated with outbreaks (Orsi et al.
2011) (Orsi and Wiedmann 2016)
Table 2-1. Classification of L. monocytogenes by lineage
Outbreak
characteristics
Commonly
cultured from
various sources,
associated with
most human
outbreaks

Lineage

Serotypes

Pathogenicity

Source

I

1/2b, 3b, 3c,
4b

Very low
genetic
diversity

II

1/2a, 1/2c, 3a

High genetic
diversity

Most isolated
from food and
food-related
sources, sporadic
outbreaks

(Piffaretti et
al. 1989)

III

4a, 4b,4c

Intermediate
genetic
diversity

Isolated in
ruminants, mot
associated with
outbreaks

(Rasmussen
et al. 1995)

IV (formerly
IIIB)

4a, 4b, 4c

Not known

Isolated in
ruminants, not
associated with
outbreaks

(Ward et al.
2008)

(Piffaretti et
al. 1989)
(Wiedmann et
al. 1997)
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Exposure to L. monocytogenes occurs via contaminated foods including ready-to-eat deli
meats, unpasteurized dairy products, and increasingly more frequently raw produce.
Annually about 1,500 individuals are infected of whom 255 are killed (Scallan et al.
2011).

2.2. Epidemiology
A recent surveillance report indicates that between 2009 and 2011, listeriosis had a
case fatality rate of 21% (CDC 2013). An inconsistent incubation period and clinical
presentation of listeriosis mimicking viral illness can preclude effective diagnosis and
result in delayed treatment with increased morbidity and mortality. Advances in
technology for identifying agents responsible for foodborne outbreaks allow for a rapid
response once the etiology is determined, but effective therapeutic intervention against L.
monocytogenes is still precluded by incomplete characterization of the bacterial-host cell
interaction at the level of the gastrointestinal tract.
Understanding where a pathogen can survive and multiply, or their reservoirs is
an essential step in pathogen control. Unfortunately, Listeria spp. have robust genomes
allowing for adaption to and survive in many places, including the soil, water, and
vegetation, but Listeria spp. are primarily associated with soil and decaying vegetables
(Vivant et al. 2013).
L. monocytogenes has a host of virulence factors that are expressed to facilitate
survival, adhesion, invasion, and eventual cell-to-cell spread throughout the body while
overcoming host immune defense. These virulence factors are listed in Table 2-1 below,
and several will be further discussed in successive sections; however, before L.
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monocytogenes can infect a host, it must gain access to the host through a transmission
vehicle, primarily food, but, while rare, it is possible to contract L. monocytogenes
through direct (wounds) and person-to-person contact.
2.3. Listeriosis – foods, risk factors, and treatment
The disease primarily associated with L. monocytogenes infection is called listeriosis;
however, it has also been associated with gastroenteritis (Bhunia 2007). There have been
many outbreaks involving L. monocytogenes in this decade.
Table 2-2. L. monocytogenes outbreaks between 2011 to 2016.

147

No. of
fatalities
43

Fatality
(%)
29.3

2012

22

4

18.2

14

2013

6

1

16.7

5

2014

8

1

12.5

2

2014

35

7

20

12

2015
2015

10
30

3
3

30
10

4
10

2016

19

1

5.3

9

2016

2

1

50

1

2016

9

3

33.3

4

Year

No. of cases

2011

States

Vehicle

28

Cantaloupe
Ricotta
Cheese
Cheese
Dairy
products
Carmel
Apples
Ice Cream
Soft Cheese
Packaged
Salad Mix
Raw Milk
Frozen
Vegetables

CDC
Foods of particular concern for L. monocytogenes contamination are minimally processed
foods such as hot dogs, deli or lunch meats (especially from the deli counter), pate,
smoked meats and fish, soft or unpasteurized cheeses (queso fresco); and fresh fruits and
vegetable such as cantaloupe, apples, spinach, and lettuce. People that are at an elevated
risk of systemic listeriosis are individuals with suppressed, compromised, developing, or
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underdeveloped immune systems. This high-risk group includes cancer and organ
transplant patients receiving immunosuppressants, HIV/AIDS patients, very young
individuals, the elderly, and pregnant women and their fetuses. Healthy individuals are at
risk for the rare, gastrointestinal form and are typically infected by consumption postprocessing contaminated foods (Bhunia 2007).

2.4. Gastrointestinal infection
The self-limiting, gastrointestinal form of L. monocytogenes infection primarily
affects healthy adults rather than children. Foods typically associated with these
outbreaks are smoked fish, cheese, cold rice salads, tuna salad, and corned beef.
Gastrointestinal infection requires a high infectious dose of 106 - 108 cfu/g. The
incubation period is typically 24 hours but can range from 6-10 days. The mechanism is
unknown; however, Listeria is not known to produce endotoxins, but rather it is
suspected that direct invasion and disruption of gastrointestinal cells and mucosa is
responsible (Ooi and Lorber 2005). Symptoms that characterize listerial gastroenteritis
include fever, headache, nausea, abdominal pain, and watery diarrhea.

2.5. Systemic Listeriosis
Systemic for if L. monocytogenes infection is called listeriosis, a disease with low
morbidity, but high mortality. Listeriosis affects immunocompromised individuals
including, individuals taking immunosuppressant drugs, HIV/AIDs patients, the young,
the elderly, pregnant women and their fetuses, alcoholics, and individuals who have
diabetes. The hallmark of systemic spread is the ability of the bacterium to breach the
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intestinal barrier and is circulated through blood and the lymphatic system to
extraintestinal organs and tissues. Within 24 hours the bacteria can be cultured from the
liver, mesenteric lymph node, spleen, and gall bladder (Burkholder and Bhunia 2010).
Without intervention, Listeria can spread and infiltrate the blood-brain and feto-placental
barriers. An inconsistent incubation period and clinical presentation of listeriosis
mimicking viral illness can preclude effective diagnosis and result in delayed treatment
with increased morbidity and mortality. In non-pregnant individuals, the systemic
disease is characterized by fever, headache, malaise, septicemia, meningitis, and liver
abscess (Bhunia 2007).

2.6. In utero and placental transmission
Listeria infection in pregnant women is not particularly detrimental to the mother,
typically resulting in the gastrointestinal form of infection (symptoms described in
section 2.3.3); however, when vertically transmitted to the fetus it can result in
spontaneous abortion, stillbirth, premature labor, or neonatal infection, depending on the
gestational age (Bakardjiev et al. 2006). Pregnant women are 18 times more likely to
have listeriosis than non-pregnant women, while is most likely a product of the
suppression of cell mediated immunity during pregnancy (Lamont et al. 2011). Listeria
infections are difficult to diagnose during pregnancy because only 30% of the known
cases of maternal L. monocytogenes infections are symptomatic and L. monocytogenes is
only detectable in blood samples of only 36% of asymptomatic cases (Mylonakis et al.
2002). Location of neonatal infection is paramount regarding the outcome of the neonatal
infection and are termed early and late onset. If the neonate is infected during gestation
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then and shows septicemia upon birth, it is termed early onset. If the neonate is
infected as it breaches the birth canal onset of symptoms occurs about 14 days after birth
and typically manifests as meningitis (Bhunia 2007).

2.7 Pathogenesis
The pathogenesis of several pathogens is dependent on the ability of the pathogen
to breach host barriers, including the skin and mucosal, epithelial, blood-brain, or
placental.

Moreover, during the intestinal phase of infection Listeria must survive the

harsh environment of the gastrointestinal tract, including low pH, bile salts, mucus,
antimicrobial peptides, and the host gut microbiome. The pathogen responds to these
environments through stress genes regulated primarily by PrfA and Sigma B (Xayarath
and Freitag 2012). The pathogenesis of L. monocytogenes is dependent on the invasion
of the gut epithelial barrier where it has access to several tissues through the bloodstream,
invasion of the blood-brain barrier where it can cause meningitis, and, in the case of
pregnant women, invasion of the placental barrier where it can cause abortion or neonatal
infection. The critical step in L. monocytogenes systemic pathogenesis is breaching the
intestinal barrier, which includes passive invasion through professional phagocytes and
active intracellular and paracellular invasion of non-phagocytic epithelial cells.
L. monocytogenes has many virulence genes responsible for intestinal infection and
subsequent dissemination. These include genes responsible for the expression of
internalins (inlA, inlC, inlJ), listeriolysin O (LLO encoded by hly, actin polymerization
protein (actA), phosphatidyl-inositol-phospholipase C (PI-PLC encoded by plcA),
invasion-associated protein (iap), and virulence regulator (encoded by prfA) have been
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reported as the most important virulence factors for L. monocytogenes (Camejo et al.

2011; Poulsen and Czuprynski 2013). Most of these genes are located in a particular
section of the genome calls the Listeria Pathogenicity Island (LPI-1) (Gahan and Hill
2014).

Table 2-3. Listeria monocytogenes virulence factors
Virulence Factor

Size (kDa)

Receptor

Internalin A (InlA)

88

E-cadherin

Internalin B (InlB)

65

Met,
gC1q-R/p32

104

Hsp60

60

membrane
cholesterol

90

-

cytoplasmic movement within
host cell via actin polymerization

29-33

-

Lysis of host cell membrane
vacuole

Gp96 (ER)

Adhesin

Listeria adhesion
protein (LAP)
Listeriolysin O
(LLO)
Actin
polymerization
protein (ActA)
Phospholipase C
(PI-PLC, PC-PLC)
Virulence
adhesion protein
(Vip)
Autolysin amidase
(Ami)
Fibronectin
binding proptein
(Fbp)
Metalloprotease
p60
Protein regulatory
factor (PrfA)

Function
Epithelial attachment and
invasion at gut and feto-placental
barrier
Epithelial attachment to
hepatocytes
Adhesion and invasion to
intestinal epithelial cells,
hemolysin, escape from host cell
phagosome

Adhesin
Adhesin
29
50

-

27

-

Synthesis of PLC
Adhesin
Master virulence regulatory
protein
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2.7.1. Microfold (M) cells
Homeostasis between the gut microbial community and the host immune system
is an important part of human health (Thaiss et al. 2016). There are centers of immune
cells in the gastrointestinal tract that considered gastrointestinal-associated lymphoid
tissue (GALT), which include the Peyer’s patch. M cells make up 10% of the epithelial
cells overlaying the intestinal lymphoid tissues (Kanaya et al. 2012; Tahoun et al. 2012).
These cells differ physically from their epithelial neighboring cells morphologically,
displaying a diminished brush border and significantly fewer microvilli (Tahoun et al.
2012). M-cells also differ functionally, they are highly specialized phagocytic cells that
capture luminal bacteria from the intestines and present it to the immune cells located
below in the Peyer’s Patch, including lymphocytes, macrophages, and dendritic cells
(Lelouard et al. 2012). M cells do not display specific phagocytosis, but rather uptake
any commensal or transient cells regardless of pathogenicity (Hase et al. 2009). Through
uptake by M cells (passive translocation), L. monocytogenes is able to breach the
intestinal epithelial barrier. Once the pathogen is presented to the immune cells it
expresses a set of virulence factors that allow it to escape phagocytosis and spread cell to
cell (Beauregard et al. 1997). This will be discussed further in section 2.4.5.

 Intracellular invasion via InlA

Internalins are extracellular adhesion molecules that assist in adhesion and
invasion of L. monocytogenes. Twenty-four internalins have been identified in L.
monocytogenes EGDe strain, but the mechanisms in which they all contribute to
pathogenesis is yet to be elucidated (Seveau et al. 2007). There are two internalins, A
(InlA) and B (InlB) that have been significantly studied and are well understood.
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Nineteen of the 24 internalins, including InlA and InlB possess N-terminal leucine-rich
repeat regions (LRRs), which allow for binding between bacterial Internalin and its
respective host receptor (Schubert et al. 2002).
InlA has been a very important virulence factor and integral one of L.
monocytogenes mechanisms for the invasion of non-phagocytic intestinal epithelial cells
(Lecuit et al. 2004). E-cadherin, a transmembrane protein that helps fortify the adherens
junction acts as the intestinal epithelial InlA receptor (Mengaud et al. 1996). E-cadherin
is functionally significant for the maintenance of the cell-cell junction integrity in the
intestines. The intracellular domain of E-cadherin interacts with cytoskeletal catenin,
while the extracellular domain homophilically interacts with the extracellular domain of
E-cadherin on the adjacent cell (Perez-Moreno et al. 2003), resulting in the adherens
junction. Interestingly, E-cadherin is located on the basolateral side of the polar intestinal
epithelial cell and is inaccessible to luminal L. monocytogenes, suggesting that the
interaction cannot take place in the native anatomical location. Pentecost et al. (2006)
reported that as new enterocytes replaced senescent cells, E-cadherin is exposed on the
tip off villous structures allowing the interaction between InlA and E-cadherin (Pentecost
et al. 2006). Binding of InlA to the extracellular domain of E-cadherin results in the
recruitment of -catenin cytoplasmic domain of E-cadherin, which subsequently recruits
-catenin which acts as an anchor holding the entire InlA/E-cadherin/-catenin complex
host cytoskeletal F-actin (Lecuit et al. 2000). AEHGAP10, a Rho GTPase, facilitates the
recruitment of - catenin to the adherens junction and in turn, Arp2/3 complex regulation
of actin cytoskeleton dynamics, and the invagination of the pathogen into the host cell
(Sousa et al. 2005).
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2.7.3. Intracellular invasion via Internalin B (InlB)
Internalin B belongs to the internalin family of proteins and facilitates intacellular
translocation of L. monocytogenes in many cell types, but most importantly hepatocytes
(Braun et al. 1998; Braun et al. 2000). Rather than being covalently anchored to the cell
wall, InlBs C-terminus electrostatically interacts with lipoteichoic acid (Bierne and
Cossart 2007). InlB binds to multiple host receptors; however, the most relevant is the
hepatocyte growth factor receptor (Met) (Shen et al. 2000). Though g1CqR is a receptor
for InlB, the interaction between the two is insufficient for bacterial invasion of guinea
pig cell lines, suggesting that invasion via InlB is Met dependent (Khelef et al. 2006).
Met, a tyrosine kinase that is the receptor for binding hepatocyte growth factor
(HGF), which is part of the cellular proliferation pathway (Birchmeier et al. 2003).
Though InlB and HGF bind to the same receptor, they are not competitive and bind to
different and distinct epitopes of Met (Shen et al. 2000). Met is a heterodimer composed
of 45 kDa  and 145 kDa  subunits. The extracellular domain includes the N-terminus of
the  subunit and the  subunit, while the cytoplasmic domain consists of the rest of the
. Phosphorylation of the cytoplasmic domain tyrosine molecules leads to downstream
signaling events (Birchmeier et al. 2003), including activation of phosphatidyl 3-kinase
(PI3-K) and Ras- mitogen-activated protein kinase (MAPK) pathways (Ireton et al. 1996;
Shen et al. 2000; Ireton 2013). Recruitment of Arp2/3 is facilitated by both the PI3-K
and Ras-MAPK pathways. Actin remodeling is dependent on the type of host cell and it
involves Wiskott–Aldrich syndrome protein (WASP), including WASP (N-WASP) and
WAVE (Bierne et al. 2005; Hamon et al. 2006). Ena/VASP, responsible for elongating
actin filaments activates the polymerization process (Bierne et al. 2005), which is
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assisted by cofilin (Bierne et al. 2005; Hamon et al. 2006), which sis implicated in
clathrin-mediated endocytosis (Marmor and Yarden 2004; Veiga and Cossart 2005;
Seveau et al. 2007).

2.7.4. Paracellular translocation via LAP
The Listeria Adhesion Protein (LAP: 104 kDa) has been identified as a
noncanonical L. monocytogenes virulence factor. LAP is a bacterial bifunctional alcohol
acetaldehyde dehydrogenase (Aad) enzyme encoded by lmo 1634 gene that can be
identified intracellularly, in the cell wall, and is secreted from L. monocytogenes (Kim et
al. 2006). LAP is secreted through the alternate secretory pathway SecA2 and reassociates with the bacterial cell through a mechanism currently being elucidated
(Burkholder et al. 2010). Cytoplasmically, LAP is a housekeeping enzyme implicated in
glycolysis under anaerobic conditions; however, it also moonlights as a cell wall
anchored adhesion factor in L. monocytogenes. LAP was identified as a bi-functional
enzyme which consists of an N terminal NAD dependent aldehyde dehydorgenase
(ALDH) and a C terminal alcohol dehydrogenase (ADH) domain (Jagadeesan et al.
2010).
Epitope masking of whole L. monocytogenes cell by monoclonal antibody MabH7
identified LAP as an adhesin for intestinal cell lines (Pandiripally et al. 1998, Jaradat et
al. 2003). Importantly, the was confirmed using a LAP insertion mutant KB208, which
showed reduced adhesion to ileo-cecal HCT8 and enterocyte like Caco-2 cells and
rescued by the expression of LAP episomally in the LAP deficient mutant (Kim et al.
2004). This was further confirmed by expressing LAP in a recombinant Escherichia coli,
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which exhibited increased binding to Caco-2 cells compared to the wild-type E. coli.
Taken together, these data suggest that LAP is a prominent listeria adhesion molecule.
In vitro cell based, molecular, and biochemical study identified surface expressed
host-cell Heat shock protein 60 (Hsp60) as the host receptor for LAP (Wampler er al
2004, Jagadeesan 2010, Burkholder and Bhunia 2010). Both transposon and isogenic
directed plasmid insertional LAP-deficient mutants have been tested against the wild-type
parental strain, and all LAP mutants exert diminished adhesion to Caco-2 cells and
attenuated pathogenic effect both in vitro and in vivo murine models (Pandiripally et al
1999; Jaradat et al 2003; Kim et al 2006; Burkholder et al 2009). Using in vitro cell
assays, adhesion to Caco-2 cells and subsequent NF-B activation was diminished in the
absence of LAP by genetic manipulation, knockdown of host Hsp60 by RNAi, or by
blockade of host Hsp60 by monoclonal antibody (Wampler et al 2004; Burkholder and
Bhunia 2010; Drolia et al 2016). Orally dosed murine models demonstrate an attenuated
capacity for both disseminated infection and a reduced insult to intestinal epithelial
integrity by the LAP-deficient mutant compared to both the wild type and Internalin A
deficient strains (Burkholder et al 2009; Drolia et al 2016). In the most recent study,
using both purified recombinant proteins as well as wild-type and LAP-deficient L.
monocytogenes, LAP-Hsp60 interaction was shown to be important for activation of NFB activity, MLCK-mediated cellular junction disruption, and to result in increased
paracellular migration of L. monocytogenes across Caco-2 monolayers (Drolia et al
2016). Taken together, this evidence strongly suggests a direct role for LAP-Hsp60
interaction in the enteric phase of infection.
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Hsp60 is a ubiquitous evolutionary conserved chaperone protein. Cytosolic
Hsp60 has been shown to positively regulate NFB activation via direct interaction with
IKK/ (Chun et al 2010) and may be involved in pre-apoptotic signaling (Zhu et al
2016). Additionally, and uncoupled from its chaperone function, surface expression and
secretion of Hsp60 in various cells types has been well described. It has been established
that Hsp60 is able to act as a receptor for Staphylococcus aureus fibronectin binding
protein A (FbpA) resulting in internalization (Dziewanowska et al., 2000).

2.7.5. Extraintestinal dissemination and cell-to-cell spread
Whether actively or passively, once L. monocytogenes has translocated across the
epithelial barrier it then spreads to extracellular tissues including the liver, spleen,
mesenteric lymph node, gall bladder, and lungs via blood circulation and the limbic
system to cause systemic listeriosis. To do so it must be able to escape phagocytic
immune cells, multiply intracellularly, facilitate movement through the cytoplasm to the
cell membrane, and enter adjacent cells allowing the pathogen to move from cell to cell.
Upon entry into the host cell the bacteria secrete listeriolysin O (LLO), a cholesterol
dependent lysin that allows that bacteria to escape the vacuole or phagasome (Henry et al.
2006; Shaughnessy and Swanson 2007). In addition to LLO, L. monocytogenes
expresses Phosphatidylinositol-specific phospholipase C (PI-PLC) that also aids in
phagosome escape (Camilli et al. 1991). Upon secretion of these virulence factors,
especially LLO and the rapid acidification of the vacuole after L, monocytogenes
invasion the vacuole become permeable and the bacteria is able to escape (Beauregard et
al. 1997). Because LLO is indispensable to phagosome escape and the receptor is
cholesterol, it is hypothesized that LLO is directly responsible for the perforation
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(Wadsworth and Goldfine 1999). It is important to note that in nonphagacytic cells LLO
is not necessary for vacuole escape. LLO deficient mutants show a 2 fold reduction in
vacuole escape, but in the absence of LLO the mutant cells secrete a multitude of broadrange phospholipase c (PC-PLC) and metalloprotease to facilitate escape (Gründling et
al. 2003).
Once in the cytoplasm L. monocytogenes multiplies and is able to move through
the host cell by inducing actin filament rearrangement and polymerization with cell
surface protein, ActA (Tilney and Portnoy 1989; Tilney et al. 1990). Interestingly, the Nterminal domain of ActA is sufficient to induce cytoskeletal rearrangement independent
of other bacterial determinants (Kocks et al. 1992; Lasa et al. 1997). The ActA has a
centrally located domain modulates direction and speed of movement through the cell.
This domain is composed of four proline-rich repeats that binds proteins of the VASP
family that activates the Arp2/3 complex inducing actin polymerization, mimicking
proteins of the WASP family inducing a branched filament actin tail (Geese et al. 2002;
Auerbuch et al. 2003; Gouin et al. 2005).
2.7.6. Feto-Placental barrier
Listeria monocytogenes is an important cause of maternal-fetal infections and
serves as a model organism to study these important but poorly understood events. To
breach the feto-placental barrier the bacteria must employ similar tactics as breaching the
intestinal barrier: direct invasion and cell to cell spread; however, the contribution of
these two tactics are not well understood. To understand how the bacteria, cross the fetoplacental barrier it is important to understand how the fetal and maternal tissues interact.
Humans and guinea pigs have a hemomonochorial placenta, in which maternal
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blood from uterine lining flows in surrounds fetal villous cells. The maternal blood come
in contact with fetal syncytotrophoblasts that continuously line the villous surface.
Branched microvilli make up the apical side of the syncytotrophoblast layer and facilitate
vertical gas and nutrient exchange (Benirschke et al. 2006; Benirschke et al. 2012).
These microvilli consist of intermingling immune and cytotrophoblast cells and have
extra-villus extensions that anchor the fetus to the placenta (Robbins et al. 2010). These
cytotrophoblast cells have abundant E-cadherin. In vitro cytotrophoblast studies have
shown that InlA deficient strains have 100-fold reduction in invasion (Lecuit et al. 2004),
suggesting that InlA play a role in barrier breach; however, in vivo these cells are not
readily accessible by the maternal blood. Furthermore, InlA and InlB mutants do not
show a reduction in fetal invasion in guinea pig and mouse models (Wollert et al. 2007;
Disson et al. 2008). A study by Ribbons et al. (2010) suggests that syncytotrophoblast,
the major source of maternal/placental tissue interaction is very resistant to L.
monocytogenes, but the extra-villous anchoring cytotrophoblasts that are the primary site
of entry (Robbins et al. 2010).

2.8. Probiotics
The term probiotic is derived from the words “pro” and “bios,” meaning “for life.”
In the early 20th century, Eli Metchnikoff, Nobel Prize winner and grandfather of modern
probiotics, observed that lactic acid bacteria (LAB) played a positive role in both
digestion and the immune system. Metchnikoff believed that with adequate consumption
of appropriate foods, these “good bacteria” could displace “bad bacteria” within the gut

23
(Mackowiak 2013). Since the discovery that certain “good bacteria” can confer health
benefits, there has been a wealth of probiotic research into a wide variety of areas
(ranging from protection against bacterial pathogens and viral infection to cancer
prevention, attempting to exploit these microbes for human benefit (Sanders et al. 2013;
Sanders et al. 2014).

2.8.1. Definitions
There have been many iterations of the definition of probiotics over the years;
however, in 2001, FAO/WHO (2002) (FAO/WHO 2002) defined probiotics as “live
microorganisms that, when administered in adequate amounts confer health benefits on
the host” (Hill et al. 2014). Notably, this definition fails to address the probiotic
mechanism of action (i.e., balancing intestinal microbiota, immunomodulation, etc.) that
previous definitions included. The change in definition was to accommodate the claim
that certain organisms are probiotic, while not fully elucidating the mechanism by which
the health benefit is conferred (Sanders 2008).
Probiotics are divergently categorized based on their ability to colonize the
intestinal tract. Resident strains (e.g., Lactobacillus spp.) are commonly found in the
human gut flora and, when supplemented, can readily colonize the human GIT. Transient
strains (e.g., Bifidobacterium spp.) cannot establish themselves within the GIT and are
excreted by the host. The duration of residence within the host is both strain- and hostspecific. The ability of a probiotic to confer its health benefits is dependent on many
factors, including strain specificity, host microbiome profile, mode of application (e.g.,
capsule, kefir, or yogurt), and ecology of the supplement (monoculture or mixture).
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Prebiotics, which will be addressed later in this chapter, are sometimes included with the
probiotic to enhance the probiotic activity of the strain or strains.
Like all microorganisms, probiotics are identified taxonomically by their genus,
species, and strain. Over the past few decades, however, many probiotic species have
been identified, most of which are Gram-positive, bile-resistant lactic acid bacteria
(LAB). The most important genera include Lactobacillus, Lactococcus, Enterococcus,
Streptococcus, Pediococcus, Leuconostoc and Bifidobacterium, while the most common
types used are Lactobacillus and Bifidobacterium (Volzing et al. 2013; Didari et al.
2014).
Table 2-4. Commonly used probiotics
Resident strains

Transient strains

Lactobacillus
acidophilus
Lactobacillus
salivarius
Bifidobacterium
bifidum
Bifidocacterium
infantis
Bifidobacterium
longum
Bifidobacterium
animalis
Streptococcus
faecalis
Streptococcus
faecium
Saccharomyces
boulardii

Lactobacillus
casei
Lactobacillus
rhamnosus GG
Lactobacillus
bulgaricus
Lactobacillus
yoghurti
Lactobacillus
brevis

Cocktails
VSL#3: Streptococcus thermophilus, Bifidobacterium
breve, Bifidobacterium longum, Bifidobacterium
infantis, Lactobacillus acidophilus, Lactobacillus
plantarum, Lactobacillus casei, Lactobacillus
bulgaricus
Lacteol Fort: L. acidophilus, lactose monohydrate,
anhydrous lactose
BLO: B. breve Yakult, L. casei Shirota,
oligossacharides
Ecologic 641: L. acidophilus, L. casie, L. lactis, B.
bifidum, B. bacterium lactis
Bio-three: Enterococcus faecalis T-110, Clostridium
butyricum TO-A, Bacillus mesemtericus TO-A

Lactobacillus kefir
Lactobacillus delbrueckii
Lactobacillus plantarum
Lactobacillus grasseri
Lactobacillus reuteri
Enterococcus faecium
Streptococcus lactis
Streptococcus thermophilus
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To be considered a probiotic, microbes must meet certain criteria (Hill et al.
2014). Table 2-6 denotes the notable characteristics of probiotics, but generally a
probiotic must be Generally Recognized as Safe (GRAS), able to survive in the low pH
environment of the stomach and be resistant to bile and pancreatic juices, persist in the
gut, confer general health benefits to the host, and be maintained stably during
processing, storage, and application.
Table 2-5. Criteria of an ideal probiotic
• Accurate taxonomic identification
• Accurate antibiotics resistant/sensitivity profile
• Able to colonize host (transient or resident)
• Generally recognized as safe (GRAS)
• Maintain viability in host physiological conditions (bile, hydrochloric acid, pancreatic
juice, high and low pH of the intestines and stomach)
• Persistence in host GIT
• Adherence to receptors in host intestinal epithelium
• Immunostimulation and immunimodulation activity
• Nonpathogenic
• Maintain antimicrobial activity at target site
• Maintain cell viability at target site
• Inability to exchange genetic information (genetic stability)
• Maintain viability a activity during processing, storage, and delivery
Adapted from Amalaradjou and Bhunia, 2012

2.8.2. General health benefits of probiotic bacteria
Probiotics can be administered in a variety of ways, in either mixed or
monoculture. They can be consumed as a supplement in pill or capsule form, or in foods
including fermented milk (kefir or yogurt), smoothie drinks, fruit juices, wine, chocolate,
fermented sausage, fresh sauerkraut or fresh pickles, and cheeses. There has recently
been an increase in probiotic-containing yogurt used to coat an assortment of nutritional
supplement bars, dried fruits, pretzels, and a host of “healthy” desserts. An effective dose
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of probiotics must include a minimum of 5 billion colony-forming units of probiotic
bacteria (CFU)/day that administered daily for a period of 5 days provides health benefits
(Gronlund et al. 1999; Williams 2010). It is generally understood that the health benefits
of the gut microbiome are due to a synergistic effect among the strains within the biome,
and this synergistic effect can be extended to the probiotic culture, thus, mixed cultures
tend to confer greater benefits than monocultures.
While many probiotics confer health benefits; the benefits and mechanism of
action are strain-specific and may not be applicable for all probiotics (Hill et al. 2014).
Lactobacillus, for example, elicits variable cytokine profiles that are dependent upon the
species and strain administered (Christensen et al. 2002; Latvala et al. 2008; Vissers et al.
2010). The health benefits of probiotics have been well documented by a wealth of
published research results (Williams 2010; Nagpal et al. 2012; Shen-Shih and Tzu-Ming
2012) that include food digestion and nutrient metabolism, short-chain fatty acid (SCFA)
production through carbohydrate fermentation, cholesterol reduction, mucoidal immune
modulation, enhanced mucus production within the GIT, antimicrobial peptide
production, enhancement of epithelial barrier integrity, and equilibration of host gut
microbiota.

2.8.3. The safety of probiotics therapy
Bacteria have been added to food for many years to enhance flavor, produce texture
changes, and provide specific health benefits. They are added to food pre-production
(starter cultures) as well as post-production (functional food additives). When probiotics
are added to prevent or treat enteric pathogenic disease, the probiotic itself must be
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nonpathogenic to the host. Commonly-used probiotic lactic acid bacteria (e.g.,
Lactococcus, Lactobacillus, and Bifidobacterium) are Generally Regarded as Safe
(GRAS); however, some strains have been known to be opportunistic human pathogens
in individuals with underlying, immunocompromising health conditions (Boyle et al.
2006). Despite these findings, there have been few systematic safety studies performed.
The Agency for Healthcare Research and Quality (AHRQ) released a study in 2011
(Hempel et al. 2011) seeking to evaluate the potential health risks of probiotic
administration. Within this review, they evaluated 622 studies of probiotic
microorganisms and concluded that, while there was no apparent elevated risk of human
illness due to supplementation with the probiotic bacteria administered in these studies,
there is a significant lack of investigation of potential risk factors associated with
probiotic supplementation within probiotic studies in current literature. In summation,
the study found that current literature was unable to address safety concerns regarding
probiotic supplementation. The WHO/FAO released a report in 2002, which suggested
that there are four potential side effects of probiotics: (A) translocation to the
bloodstream, leading to systemic effects, (B) “deleterious metabolic activities,” (C)
overstimulation of the host immune system, and (D) gene transfer to commensal
microbiota, leading to an adverse effect within the gut microbiota or directly to the host,
such as transfer of antibiotic resistance genes to opportunistic pathogens commonly
found in the gut microbiome or overproduction of lactic acid leading to lactic acidosis in
the patient (Doron and Snydman 2015). Given this, and the strain specificity of probiotic
action, it is important to screen potential probiotics for the presence of virulence factors,
antimicrobial resistance, antibiotic sensitivity and antibiotic gene transfer, as well as the
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potential for the uptake of pathogenic virulence genes (Amalaradjou and Bhunia 2012;
Didari et al. 2014). It is important to note that while these complications might occur in
certain rare and isolated settings, the transient nature of probiotics in the GIT decreases
the likelihood that they will occur. Both the Scientific Committee on Animal Nutrition
(SCAN) and the FAO have developed guidelines for probiotic additives to animal feed
and food consumed by humans, respectively. Both strategies employ methods that test
for the aforementioned factors of safety risk (i.e., genotypic and phenotypic analyses for
virulence factors, antimicrobial resistance, gene transfer, etc.), with a notable exception,
that the FAO also requires probiotics to pass double blind, randomized, placebocontrolled human clinical trials. Within these studies and reviews two areas of probiotic
used have been identified, probiotic use for the general public through food additives and
dietary supplements and probiotic use on an individual basis for health intervention as a
drug or vaccine. The risk assessment for general use of probiotics as a food additive or
dietary supplement reveals that the potential risks (lactic acidosis, persistent gut
inflammation, and antibiotic resistant gene transfer to potential pathogens) are greater
than the potential general health benefits (gut microbiome balance or flavor
enhancement). When probiotics are used on an individual basis to treat specific health
problems, such as enteric pathogens, acute infectious and antibiotic associated diarrhea,
and irritable bowel syndrome, the potential risks are balanced by the specific health
benefits conferred to combat the specific diagnosis (Sanders et al. 2010).
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Table 2-6. Proposed probiotic mechanisms of action against human health conditions and
benefits
Health condition or
benefit
Proposed Mechanism
Antagonism
Increased antibody production
Colonization resistance
Limiting access of enteric pathogens (pH control by acid
production, bacteriocins, antimicrobial peptides)
Enteric pathogen resistance Modulation of tight junction integrity, production of SCFA
Aid in lactose metabolism
Bacterial lactase acts on lactose in the small intestines
Decrease toxic metabolite production
Normalize small bowel flora
Small bowel bacteria
overgrowth
Antimicrobial activity
Production of SCFA
Regulate Th1/Th2 cell activation
Modulate IL-10/IL-12/IL-6 activity
Immune system modulation Stimulation from phagocytic and dendrocytic cytokines
Anti-mutagentic and anti-carcinogenic activity
Detoxification of carcinogenic metabolites
Anticolon cancer effect
Immune stimulation and modulation
Toxic microbial metabolite modulation of host microbiota increases carbohydrate
production
metabolism of the community
Prevention of antigen translocation into blood stream
Antiallergenic activity
Modulation of immune response to increase in antigen
Uptake of cholesterol by gut microflora
Heart disease, blood lipids
Modulation of bile salt hydrolase (BSH) activity
Competitive exclusion
pH modulation
SCFA production
Urogenital infections
Modulation of urogenital microflora
Necrotizing enterocolitis
Reduce IL-8 response
Rotovirus gastroenteritis
Increased viral specific IgA response
Enhance mucosal barrier function
Decreased inflammatory response
Inflammatory bowel disease Immune modulation
Reduced proinflammatory cytokines
Crohn's disease
Reduced inflammation
Competitive exclusion
Modulation of urogenital flora
Human immunodeficiency
Regulation of mucosal T-cell populations,
virus (HIV)
Mucosal immune stimulation and modulation
Adapted from Amalaradjou and Bhunia, 2012; Nagpal et al., 201
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2.9. Probiotic mechanisms of action
Several mechanisms of probiotic action have been proposed (Table 2-6); several, of
which, are discussed in this section.

2.9.1. Antimicrobial activity of probiotic bacteria
Microorganisms have evolved to express several antimicrobial properties to improve
their ability to compete for limited ecological recourses, and probiotic bacteria are no
exception (Amalaradjou and Bhunia 2012). Within the ecology of the human GIT,
probiotics express these antimicrobial factors to enhance their survival and, inadvertently,
enhance host protection against enteric pathogens. Probiotics suppress enteric pathogens
both directly and indirectly through the production of antimicrobial factors and
modulation of host cell expression of antimicrobial peptides, respectively.
The secretion of SCFAs by both probiotic and commensal gut microflora provide
several positive effects on host endocytes and the gut microbiota themselves, including
antimicrobial effects against enteric pathogens. SCFA have the ability to disrupt the
outer membrane of Gram-negative pathogens (e.g., Salmonella enterica serovar
Typhimurium and various E. coli strains) by inhibiting growth, disrupting osmotic
pressure and increasing permeability to other antimicrobial factors, produced by both
probiotic bacteria and host cells that can disrupt pathogen cell membranes (Alakomi et al.
2000). Aside from direct bacteriostatic or bactericidal properties, the SCFA’s propionic
and hexanoic acid promote host antimicrobial production (Alva-Murillo et al. 2012).
Oral administration of butyrate can possibly stimulate host defense peptides leading to
the clearance of Salmonella (Sunkara et al. 2012). Interestingly, SCFA-producing
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bacteria are apparently immune to the antimicrobial effect of SCFAs, providing them an
additional selective advantage within the ecology of the gut microbiota (Alva-Murillo et
al. 2012). SCFAs produced by probiotic bacteria reduce the pH of the intestinal lumen
thereby inactivating several enteric pathogens (Carey et al. 2008), and SCFAs also
regulate colonic T reg cell homeostasis for improved gut health (Smith et al. 2013)
Bacteriocins and microcins are antimicrobial agents commonly secreted by Grampositive and Gram-negative bacteria, respectively. Bacteriocins are a heterogeneous
group of secretory molecules that bind to species-specific extracellular receptors on
enteric bacteria (sensu lato), including pathogens, that cause morphological (typically
pore formation) or metabolic changes leading to cell death (Bhunia et al. 1991; Jack et al.
1995; Daw and Falkiner 1996). Depending on the molecular weight and the inhibitory
spectrum of bacteriocins, there are four general classes of bacteriocins produced by lactic
acid bacteria (Klaenhammer 1993; Cotter et al. 2005). In contrast, microcins are
antimicrobial peptides that target the enzymes involved in DNA, RNA, and protein
structure and synthesis (Duquesne et al. 2007). There have been many studies in the past
two decades elucidating the bactericidal or bacteriostatic activities of bacteriocins
produced by probiotic bacteria. Lactobacillus acidophilus, a commonly used and
commercially-available probiotic, can inhibit Salmonella, Shigella, Pseudomonas, and
Vibrio species in vitro, likely by the inhibitory activity of the bacteriocin, acidophilin
(Vila et al. 2010; Brown 2011). A bacteriocin secreted by L. plantarum has broad
spectrum inhibitory activities against both Gram-positive and Gram-negative bacteria,
including many pathogens such as S. aureus, L. monocytogenes, and many E. coli strains
(Kumar Tiwari and Sheela 2008). A broad spectrum bacteriocin (ABP-118) secreted by

32
L. salivarius UCC 118, although ineffective against other Lactobacillus species, is highly
inhibitory to Listeria, Bacillus, and Staphylococcus (Dunne et al. 2001; Flynn et al.
2002). In further in vivo studies, a mutant strain of L. salivarius was unable to produce
ABP-118 and had no protection against L. monocytogenes infection, whereas the WT
control probiotic conferred protection (Corr et al. 2007; Sherman et al. 2009).
Some probiotic bacteria also directly exert their antimicrobial properties by
adhering to the host intestinal epithelial cells and effectively reducing pathogen
adherence (Collado et al. 2009). Several in vitro studies involving pretreatment with
individual strains of Lactobacillus species (viz., L. acidophilus, L. rhamnosus, L.
helveticus, and L. paracasei) revealed the successful inhibition of adhesion and
translocation of several pathogens, including enterohemorrhagic E. coli (EHEC),
enteropathogenic E. coli (EPEC), L. monocytogenes, and Salmonella spp. (Zareie et al.
2006; Johnson-Henry et al. 2008; Medellin-Pena and Griffiths 2009).
Alternatively, probiotic bacteria can indirectly suppress enteric pathogen function
by eliciting an enhanced antimicrobial response by the host intestinal cells. The two
major classes of antimicrobial peptides produced by human intestinal cells are defensins
and cathelicidins. Although cathelicidins are constitutively produced in the human GIT,
butyrate produced by both commensal and probiotic bacteria can also induce cathelicidin
production (Schauber et al. 2003; Sunkara et al. 2011). Prophylactic oral administration
of butyrate has been used to reduce and control both Salmonella (Fernandez-Rubio et al.
2009) and Shigella infections (Raqib et al. 2006).
Human intestinal Paneth cells and neutrophils constitutively secrete -defensin,
while various other epithelial cells constitutively secrete -defensin. Defensins have
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antimicrobial properties and are produced in the intestine to suppress enteric pathogens
(Kudryashova et al. 2015). Several studies have revealed that probiotic bacteria (e.g., E.
coli Nissle 1917, E. coli DSM 17252, and VSL#3 consisting of four strains of lactobacilli
(Lactobacillus casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus),
three strains of bifidobacteria (Bifidobacterium longum, B. breve, and B. infantis), and
Streptococcus salivarius subsp. thermophilus) can induce the secretion of
-defensins (Wehkamp et al. 2004; Schlee et al. 2007; Schlee et al. 2008; Seo et al.
2012). In studies with the probiotic E. coli Nissle, one of the best characterized
probiotics, human -defensin-2 was determined to be flagellin-mediated (Seo et al.
2012).

2.9.2. Immunomodulation by probiotic bacteria
The intestine is an important mucosal organ responsible for the absorption of
nutrients from digested food; however, the GIT is also a prominent immune organ
consisting of approximately half of the immune cells in the human body. It was
suggested in the 1970’s that the commensal bacteria of the gut play an important role in
immune modulation as the IgG response to antigens was found to be much lower in
germ-free (GF) mice than in conventional (CV) mice (Ohwaki et al. 1977). Additionally,
it has been revealed that the presence of gut microbiota markedly influences CD4+ and
CD8+ cell pools within gut-associated lymphoid tissue (GALT) (Bandeira et al. 1990).
Probiotic bacteria are of particular importance in modulating the mucosal immune system
of the gut. These tissues are collectively known as the gut-associated lymphoid tissues
and primarily consist of the mesenteric lymph node, Peyer’s patches, and hematopoietic-
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derived cells such as lymphocytes, dendritic cells, and isolated lymphoid follicles, which
are the primary location of intestinal B cells (Caballero-Franco et al. 2007). Studies have
revealed that colonization of the gut leads to increased numbers of intraepithelial
lymphocytes, antibody-producing cells, and antibody concentration in sera (Hakansson
and Molin 2011). The lamina propria secretes IgA (sIgA) that is luminal bacteriaspecific in CV mice; however, sIgA is not present in the GIT of GF mice, suggesting that
the gut microbiota stimulate the production and secretion of intestinal IgA. The sIgA
protects the host against the luminal microbiota that penetrates the epithelial barrier
(Macpherson and Harris 2004). Furthermore, Bacteroides thetaiotaomicron-colonized
gnotobiotic mice implanted with hybridoma cells producing B. thetaiotaomicron-specific
IgA had a decrease in cecal antigen (Peterson et al. 2007). These results suggests that the
commensal gut microbiota and probiotic bacteria influence the intestinal immune system
and specific host immune tolerance of the commensal microbiota.
There are three postulated mechanisms for probiotic modulation of the innate
immune system: (i) functional regulation of intestinal epithelial cells through direct
contact, (ii) probiotic bacteria transported through micro-fold (M) cells activate
phagocytic cells within the Peyer’s patches, and (iii) dendritic cells (DC) in the lamina
propria recognize probiotic bacteria through pattern recognition receptors (PRR), such as
Toll-like receptors (TLR) (Hardy et al. 2013).
Many probiotic bacteria adhere and interact directly with intestinal epithelial
cells, and it is believed that this is the mechanism they exert to modulate host immunity.
A mixture of probiotic bacteria, VSL#3, increased the production and secretion of mucin
in vitro in both human colon epithelial cells (LS 174T) and rat colonic loops (Caballero-
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Franco et al. 2007). Probiotic and commensal bacteria have the ability to influence the
inflammatory signaling pathway through direct contact with intestinal epithelial cells.
The nuclear factor kappa B (NF-B is the prominent inflammatory signaling pathway.
Under anti-inflammatory (non-stimulatory) conditions, the cytoplasmic NF-B is bound
to an inhibitor molecule, which renders it inactive; however, when inflammation is
stimulated, the inhibitor molecule is phosphorylated, making NF-B active and
subsequently activates transcription of proinflammatory genes in the nucleus. Several
studies have revealed that probiotic strains are able to inhibit phosphorylation of the NFB inhibitor and thereby negate inflammation. Interestingly, this also inhibits the
secretion of IL-8, a proinflammatory cytokine, by intestinal epithelial cells, which further
negates intestinal inflammation (Thomas and Versalovic 2010).
Probiotic bacteria taken up by M cells have the potential to activate phagocytic cells
(macrophages, monocytes, and neutrophils) and natural killer cells (NK), as well as
dendritic cells. In this way, probiotic as well as commensal bacteria have the ability to
“tune” the innate immune system, which enables its rapid response to enteric pathogens.
This ability to “tune” or prime the immune system is demonstrated by the ability of
probiotic bacteria to elicit pro-IL-1 production by intestinal macrophages; thus allowing
for rapid conversion to active IL-1 (Franchi et al. 2012). This can lead to a variety of
cytokine expression and subsequent activation of immune cells. Two key cytokines
dictate the direction of an immune response, IL-10 and IL-12. IL-12 is involved in
activation of cellular immunity and cytotoxic cell function, whereas IL-10 suppresses IL12 function and reduces inflammation leading to a reduction in immune response (Shida
et al. 2006). Konieczna et al.(Konieczna et al. 2012) determined that Bifidobacterium
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spp. can induce high levels of IL-10 production in human DCs, whereas Lactobacillus
cannot. The activation of IL-10 is a key factor in priming the host immune system, while
negating a negatively inflammatory state. In a human study in which elderly participants
were supplemented with L. rhamnosus, results revealed that the probiotic-supplemented
group experienced an increase in peripheral blood NK cell counts compared to the
control (Gill and Rutherfurd 2001b; a). In vitro studies have revealed that probiotic
bacteria induce IL-12 activity in macrophages, subsequently stimulating NK activity
(Dong et al. 2010), which could be an insight into the mechanism by which certain strains
of Lactobacillus spp. potentially activate NK cells. Not only do probiotic bacteria
increase the number of peripheral blood lymphocytes, but they also enhance their
phagocytic capacity (Gill 2003). In vitro studies in RAW264.7 macrophages exposed to
cell wall extracts of B. adolescentis BBMN23, B. longum BBMN68, and L. salivarius
Ren revealed enhanced phagocytic activity via increased production of IL-6 and TNF-
(Yuanmin et al. 2011). Similarly, Kaushal and Kansal (Deepti and Vinod 2014)
determined that mice orally administered with L. acidophilus and B. bifidum had an
increased production of reactive oxygen intermediates and enhanced phagocytic activity
in macrophages. Many of the immune functions that are carried out by immune cells are
mediated by cytokines. Administration of probiotic bacteria has a major effect on
modulating cytokines. For example, specific strains of probiotic bacteria have increased
the expression of INF-, IFN-, and IL-12 (Arunachalam et al. 2000). Similarly, longterm consumption of probiotic bacteria in yogurt increased production of IL-1, IL-1, IL6, IL-10, IL-12, IL-18, INF-, and TNF- by monocytes and DC (Cross 2002; Gill and
Guarner 2004; Niers et al. 2005).
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Probiotic and pathogenic bacteria have conserved extracellular features that interact
with host immune cell PRR like their interaction with epithelial cells, discussed
previously. For example, the flagellin expressed by some probiotic bacteria for
chemotaxis and cellular adhesion also interacts with dendritic cells sequestered in the
lamina propria and stimulates production of cytokines which are responsible for initial
immune responses, chemokine production and antimicrobial peptide secretions
(Kinnebrew et al. 2012). Probiotic bacteria have a potent ability to stimulate innate
immunity, which plays a role in the stimulation of adaptive immune modulation.
Probiotic bacteria have an “adjuvant” effect, meaning they possess the ability to stimulate
a humoral immune response (Hall et al. 2008; Belkaid and Hand 2014). For example,
antigen-presenting dendritic cells stimulate a T-cell response. Several studies have
revealed that L. rhamnosus can regulate Th1/Th17 cells by an increased pro- Th1/Th17
cytokine release by DC (Lin et al. 2009; Yu et al. 2010). B-cell-secreting IgA is an
important part of humoral mucosal immunity. Orally administered L. gasseri increased
intestinal IgA secretion and induced TGF- production in DC (Sakai et al. 2014). There
have been several animal and clinical studies conducted in an attempt to elucidate the
immunomodulatory effects of probiotic bacteria. Together, they present a multifaceted
and very complex network of cooperation among probiotic bacteria, epithelial cells,
GALT, and immune cells.

2.9.3. Enhancement of intestinal barrier function by probiotic bacteria
The physical barriers that separate self from non-self are the first line of defense
in the innate immune system. With respect to enteric pathogens, this is the epithelial
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barrier of the GIT. This intestinal epithelial barrier has mechanisms that enhance barrier
function such as mucus secretion, chloride and water secretion, and cellular junction
maintenance (Thomas and Ockhuizen 2012). Loss of barrier function is commonly
referred to as “leaky gut.” It is well-established that disruption of intestinal barrier
function can lead to inflammatory bowel disease (IBD), several diarrheal diseases, enteric
infection, and other autoimmune diseases (Xavier and Podolsky 2007). Probiotic bacteria
can prevent or improve leaky gut resulting from food antigens, enteric pathogens,
proinflammatory cytokines, and immune dysregulation (O'Hara and Shanahan 2007).
The epithelial barrier is covered by a protective layer of mucus largely produced
by goblet cells throughout the GIT. The proportion of goblet cells to epithelial cells is 416% depending on the location within the GIT. Goblet cell occurrence and mucus
thickness is least in the duodenum, increasing in occurrence and thickness through the
small intestine until the descending colon (Goto and Kiyono 2012). Several probiotic and
commensal bacteria are able to influence goblet cell number and mucus production (Ng
et al. 2013; Tomas et al. 2013; Pelaseyed et al. 2014). To translocate across the epithelial
barrier, pathogenic bacteria must first penetrate the protective gel layer of proteolyticresistant mucin. Many bacteria have developed mechanisms to degrade the mucin to
uptake nutrients or gain access to the epithelial cells underneath (Ohland and
MacNaughton 2010). Intestinal inflammation plays an important role in pathogen
invasion of mucus layer because under inflammatory conditions the mucus layer becomes
thin, granting access to potential pathogens that would otherwise not have been able to
penetrate the mucoid layer (Ng et al., 2013). While it is well-established that several
probiotic strains of Lactobacillus and VSL#3 can stimulate mucus production (Mack et
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al. 2003; Caballero-Franco et al. 2007), the mechanism of action has been elusive.
However, in a recent study using Ruminococcus gnavus E1 revealed there was an
increased expression of the mucin-encoding genes MUC1, MUC 2 and MUC3 which
resulted in increased glycosylation by goblet cells that correlated with an increase in
mucin production (Graziani et al. 2016).
The integrity of the epithelial barrier is largely due to cell to cell junction
complexes. These complexes consist of the tight junctions, adherent junctions, gap
junctions and desmosomes. The tight junction is comprised of some 50 proteins that
consist of transmembrane proteins that are anchored to the actin cytoskeleton.
Regulation of these proteins are paramount to the integrity of the junction, and
subsequently the epithelial barrier. Several enteric pathogens have evolved mechanisms
to circumvent and cross the epithelial barrier via both intracellular and paracellular means
(Guttman and Finlay 2009; Goto and Kiyono 2012). Similar to the thinning of the mucus
layer, chronic inflammation plays a role in barrier function and promotes pathogen
permeation of the barrier. In in vitro and in vivo studies, L. plantarum restored tight
junction protein integrity after disruption with unconjugated bilirubin administration
(Zhou et al. 2010). Similarly, pretreatment with L. acidophilus or S. thermophilus both
decreased permeability in vitro and in vivo (Ahrne and Hagslatt 2011).

2.10.Probiotic control of enteric pathogens
There has been substantial research into the use of probiotic bacteria to control
enteric pathogens over the past five decades. The scope of the research has narrowed
from understanding which probiotic strains or mixtures could positively enhance the
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resistance of humans or feed animals to pathogenic bacterial infections to bioengineering
designer probiotic bacteria that elicit specific protective qualities against specific
pathogens. There is great potential for these bioengineered probiotics to provide 2-fold
protection, including (i) a bioengineered defensive function, and (ii) conferring the native
health benefits previously discussed in this chapter such as enhanced intestinal barrier
function and production of antimicrobial compounds. Several studies have revealed the
efficacy of wild-type and recombinant, bioengineered probiotics in suppressing enteric
pathogen infection (Salminen et al. 2010; Bhunia 2012; Dobson et al. 2012; Fijan 2014).
This next section addresses probiotic-based mediation of enteric pathogens.

2.10.1. Probiotic control of foodborne pathogens
Over the last few decades, our understanding of the relationship between the diet
and general health has evolved from the simplistic perception of primarily only an
acquisition of nutrients needed for metabolism to a greater understanding of how specific
foods promote the overall well-being of an individual (e.g., “superfoods,” antioxidants,
anti-inflammatories, etc.). This understanding fostered the use of the term “functional
foods.” Foods that, beyond simply providing nutritional value, can benefit additional
specific functions within the body, are considered functional foods (Figueroa-Gonzalez et
al. 2011). Because of their ability to specifically enhance gut health and function,
probiotics may be considered to be a functional food (Nagpal et al. 2012). Probiotics are
typically nonpathogenic microorganisms that promote health benefits when administered
in clinically-appropriate dosing. The most common probiotics are Lactobacillus and
Bifidobacterium. To be considered a probiotic, a microorganism must exert benefits in
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three ways: (i) Provide the host with organic acids (short chain fatty acids) through
anaerobic fermentation of carbohydrates that can be positively utilized by the host. There
has been a wealth of recent studies investigating the wide reach of these fermentation
endproducts, suggesting that they play a major role in brain function and cognition. (ii)
Stimulate or prime the host immune system, without causing inflammation within the
gastrointestinal tract (GIT). (iii) Exclude pathogens in the GIT from causing disease by
outcompeting them for the limited resources and space (Stecher and Hardt 2011). In
general, probiotics are known to prevent/alleviate chronic inflammatory bowel disease,
colorectal cancer, metabolic disorders, allergic response, obesity, and osteoporosis
(Azcarate-Peril et al. 2011; Ly et al. 2011; Amalaradjou and Bhunia 2012; Cate et al.
2015; Kim et al. 2016). They are also administered in preterm neonates to allow early
colonization of beneficial microorganisms (Deshpande et al. 2011)
Further, probiotics must be administered in adequate amounts to be beneficial.
Widespread colonization of the gut by probiotics can obstruct pathogen access to the
physical niche required for attachment and infection (Gaggia et al. 2010). If physical
displacement is insufficient and a pathogen is able to colonize, probiotics have several
functional attributes which allow them to effectively subvert pathogen infections within
the gut. Like many microorganisms trying to survive within a complex ecosystem,
several probiotics can inactivate pathogens through the secretion of antimicrobial
peptides, called bacteriocins (Klaenhammer 1993; Amalaradjou and Bhunia 2012). As
previously stated, probiotics stimulate the host immune system, allowing for a prompt
host immune response to host-pathogen interaction (Oelschlaeger 2010; Gourbeyre et al.
2011).
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2.10.2. Salmonella
Salmonella is a predominant cause of human foodborne disorders worldwide and
is associated with a wide variety of food, including raw poultry and eggs, fish, and fruits
and vegetables, nuts, dry milk, infant formula, spices, etc.(Carrasco et al. 2012) . It is a
zoonotic pathogen with a natural reservoir in livestock, especially chickens, which, when
consumed, transfers the live pathogen to the GI tract of the host (Foley and Lynne 2008;
Das et al. 2013). Multiple strategies have been employed to address exclusion of this
pathogen from food production and subsequently the food supply (Vandeplas et al. 2010).
Several studies have revealed that administration of probiotic microbes directly to broiler
chickens may reduce Salmonella contamination, thus reducing human exposure through
contaminated food (Van Coillie et al. 2007; Higgins et al. 2008). Higgins et al. (Higgins
et al. 2008) determined that challenging neonatal broiler chicks with Salmonella
Enteritidis and subsequently feeding them increasing doses of Lactobacillus, resulted in
up to an 85% reduction in the prevalence of Salmonella. Another study revealed that L.
rhamnosus reduced epithelial cell stress due to S. Typhimurium adhesion and invasion in
vivo (Burkholder and Bhunia 2009). Not only did administration of L. plantarum improve
the growth performance of pigs, but it also reduced fecal shedding of S. Typhimurium
(Gebru et al. 2010). Oral administration of lactic acid bacteria to broiler chickens not
only reduced the transmission of S. Typhimurium from the GI tract to the spleen and
liver, but also down-regulated SPI-1 virulence gene expression, which is necessary for
intracellular multiplication (Xiaojian et al. 2014). Interestingly, in an in vitro study using
an intestinal fermentation system with immobilized fecal microbiota, Bifidobacterium
thermophiles RBL67 inhibited S. Typhimurium when administered either pre- or post-
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challenge (Tanner et al. 2016). In contrast, hens and broiler chickens receiving a
combination of probiotics that included Bacillus subtilis, Lactobacillus acidophilus, L.
casei, Enterococcus faecium, and Bifidobacterium longum in their feed had no significant
reduction in the carriage of S. Enteritidis (Murate et al. 2015). This difference in results
highlights the strain-specific attributes of probiotic bacteria and their interactions with
pathogenic bacteria, host cells, and host microbiota, which is further supported by a metaanalysis study of competitive exclusion of Salmonella in broiler chickens conducted by
the Public Health Agency of Canada and the University of Guelph in 2013 (Kerr et al.
2013). These investigators concluded that of the 214 probiotic trials considered, the
reduction in prevalence or amount of Salmonella varied considerably (Kerr et al. 2013).
Lactococcus lactis IL1403 has been engineered to secrete the antimicrobial peptides
(AMP) Alyteserin-1a and A3APO, both of which are effective against Gram-negative
bacteria, but not Gram-positive bacteria. When AMP-expressing L. lactis is co-cultured
with S. Typhimurium or S. Infantis, the growth of both serovars was significantly
inhibited compared to the control (Volzing et al. 2013).
Because the high health and economic burden of Salmonella, considerable effort
has been directed toward determining the underlying mechanism of antimicrobial and
protective effects of probiotic bacteria against Salmonella. Asahara et al. (Asahara et al.
2011) identified a correlation between an increase in intestinal organic acids which
reduced the luminal pH and the inhibition of S. Typhimurium growth in mice
administered L. casei Shirota. Inhibition of Salmonella growth due to lowered pH has
been shown in many studies (Fayol-Messaoudi et al. 2005; Asahara et al. 2011; Dobson
et al. 2012).
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Immunomodulation of the innate and adaptive immune system by probiotic
bacteria correlates with the reduction of Salmonella intestinal and tissue counts in in vivo
mouse studies. L. casei CRL administration reduced inflammation, increased bacterial
clearance due to activated phagocyte activity, increased IgA+-producing cells, and
increased the intestinal? secretion of pathogen-specific sIgA (de LeBlanc et al. 2010).
Hence, it appears that the mechanism of reducing pathogen levels in hosts by probiotic
bacteria is multifaceted and involves reducing the luminal pH by increased organic acid
concentrations, the production of bacteriocins and modulating the innate and adaptive
immune systems (Dobson et al. 2012). Although probiotic bacteria have antimicrobial
activity against Salmonella in an animal’s intestinal tract, these bacteria can also enhance
the growth performance of these food animals.

2.10.3. Campylobacter
Campylobacter jejuni is predominantly a poultry pathogen which colonizes the
ileum and colon of the GI tract and causes gastroenteritis in humans, characterized by
fever, abdominal cramps, and diarrhea (Young et al. 2007; Dasti et al. 2010).
Pathogenesis is well-defined and can be attributed to disruption of the mucosal epithelial
barrier that occurs during campylobacter adhesion and invasion in the GIT (Boehm et al.
2011). Several studies both in vitro and in vivo have revealed that Lactobacillus spp. and
Bifidobacterium spp. can reduce C. jejuni adhesion to and invasion of cells (Schachtsiek
et al. 2004; Wine et al. 2009; Neal-McKinney et al. 2012; Tareb et al. 2013). A recent
study revealed that reducing C. jejuni adhesion by the probiotic L. gasseri SBT 2055
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(LG) was due to co-aggregation of the probiotic bacteria and C. jejuni by an interaction
between the proteinaceous cell surface of LG and C. jejuni. When protease K-treated LG
cells were used in in vitro studies, co-aggregation was reduced and adhesion and invasion
of Int-407 cells were increased compared to Int-407 cells not with treated probiotic
bacteria, suggesting that surface proteins of L. gasseri play a significant role in reducing
the adhesion and invasion of C. jejuni (Nishiyama et al. 2014). Similarly, L. helveticus
R0052, which efficiently adheres to epithelial cells, was able to competitively exclude C.
jejuni, resulting in a 55% reduction in invasion into Int-407 cells (Wine et al. 2009).
Wagner et al. (Wagner et al. 2009) through in vivo studies using defined human
microbiota-associated Balb/C mice dosed with lactobacilli and bifidobacteria after being
orally infected with either Salmonella or C. jejuni, determined that the probiotic bacteria
could successfully colonize the gut and competitively exclude both pathogens. Enhanced
colonization resistance against both pathogens was observed. A Bacillus subtilis
probiotic isolated having increased motility and an increased ability to occupy sites of
Campylobacter adhesion within the GIT, provided enhanced protection against
Campylobacter infection when administered orally to chickens (Aguiar et al. 2013).

2.10.4. Shiga Toxin-producing Escherichia coli (STEC)
STEC are becoming an increased concern as traditionally non-Shiga toxin (STX)producing E. coli are discovered to produce Shiga toxin (one or both of the STX proteins,
STX1 and STX2). In 2011, in Germany, an outbreak caused by an STX-producing
enteroaggerative E. coli (EaggEC), typically STX negative, hospitalized 3842 people,
with hundreds developing hemolytic uremic syndrome (HUS). Interestingly 88 percent of
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those cases were healthy adults (Beutin and Martin 2012; Muniesa et al. 2012). This
would suggest that STEC are capable of causing systemic infection in not only
immunocompromised individuals but also in healthy people. STEC are responsible for
sporadic cases and outbreaks characterized by hemorrhagic colitis, largely resulting from
ingestion of meat and fruits and vegetables contaminated by STEC containing fecal
matter. HUS is the more severe form of STEC infections, occurring in 5-15% of cases
(Davis et al. 2013). When the pathogen enters the intestine it begins the synthesis of
STX, which crosses the epithelial barrier, gains entry into the blood stream, and
eventually invades and damages kidney cells. The key receptor for STX is
globotriaosylceramide (Gb3), whereas globotetraosylceramide (Gb4) is the receptor
associated with the STX variant responsible for the disease in swine (Degrandis et al.
1989). Knowledge of the host cell receptor responsible for pathogen attachment can be
exploited to develop strategies for conferring resistance to the pathogen. In a recent
study, recombinant probiotic E. coli R1 expressing globotetraose, which mimics an STX
receptor on its surface, were twice daily administered to piglets 24 hours after receiving a
dose of STEC. The recombinant E. coli significantly reduced fecal toxin excretion by day
3; however, despite the reduction of intestinal toxin, the probiotic was not successful in
reducing the frequency of vascular lesions and clinical disease (Hostetter et al. 2014).
Many other studies with probiotic bacteria in mice have shown efficacy in reducing or
preventing disease when wild-type probiotics, especially Lactobacillus, are administered
prior to infection with STEC (Tsai et al. 2010; Eaton et al. 2011). In contrast, it appears
the globotetraose expressing probiotic bacteria were effective in neutralizing STX, but
not attenuating disease. As described above in the section on Salmonella, L. lactis has
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been engineered to secrete anti-Gram-negative bacterial AMP. The recombinant L.
lactis-secreting alyteserin-1a inhibited the growth of E. coli O157:H7 when co-cultured
(Volzing et al. 2013). With additional studies, this recombinant probiotic bacterium may
provide useful for suppressing STEC in both human and animal systems.

2.10.5.Listeria monocytogenes
Listeria monocytogenes is a rare enteric pathogen because it is generally not
associated with gastric distress, rather it causes a severe invasive systemic infection in
high-risk individuals such as pregnant women, newborns, the elderly, and the
immunocompromised (Swaminathan and Gerner-Smidt 2007). While L. monocytogenes
is associated with a relatively low morbidity when compared to other enteric pathogens
such as Salmonella, the mortality rate is very high (20-30%) (Voetsch et al. 2007). Kirk
et al (Kirk et al. 2015) estimated that there were 14,169 cases of L. monocytogenes
infections leading to 3,175 deaths globally in 2010. This equates to a staggering 22.4%
mortality rate. L. monocytogenes, after surviving the gastric juices of the stomach and
arriving at the intestinal tract, attaches to and invades epithelial cells both intracellularly
and paracellularly, and disseminates to the mesenteric lymph nodes (MLN), liver, spleen,
and can eventually penetrate both the blood-brain and blood-placental barriers
(Burkholder et al. 2009; Ribet and Cossart 2015). After penetrating the blood-placental
barrier, L. monocytogenes can induce microabscesses and necrosis, resulting in preterm
spontaneous abortion, stillbirth, and miscarriage (Vazquez-Boland et al. 2001; Bakardjiev
et al. 2006; Jiao et al. 2011). Several studies investigating the feasibility of probiotic
intervention of listerial infection have been performed. L. casei Shirota-fed rats not only
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had a reduced L. monocytogenes load in the GIT, spleen, liver, and feces, but also had a
delayed hypersensitivity to the pathogen suggesting an increased cell-mediated immune
response (de Waard et al. 2002). Similarly, L. delbrueckii provided a protective effect
against colonization, advanced clearance of L. monocytogenes, and an increase in IFN-
and IL-10 (dos Santos et al. 2011). This study highlights the role of host immune
modulation in probiotic-induced protection against and clearance of Listeria.
Additionally, L. plantarum can reduce the production of proinflammatory cytokines
necessary for Listeria-mediated cytotoxic effect (Puertollano et al. 2008). Bacteriocin
production by probiotic bacteria can directly inhibit pathogens. L. salivarius produces a
bacteriocin that provides protection against listerial infection (Corr et al. 2007). In
contrast, Lactococcus lactis, which produces lacticin, provides strong protection in vitro,
but failed to protect against Listeria infection in in vivo mouse and pig studies (Rea et al.
2007; Dobson et al. 2011; Rea et al. 2011). Similarly, in a recent study, Fernandez et al.
(Fernandez et al. 2015) determined that a pediocin producer, Pediococcus acidilactici
UL5 was able to affect the metabolic activity (increased production of acetic and
propionic acids) of immobilized intestinal microbiota in a bioreactor, but it was unable to
inhibit L. monocytogenes growth within the reactor. These studies highlight the species
and stain specificity of the antimicrobial action of probiotic bacteria and the potential
lack of relationship between in vitro and in vivo study results. A recombinant L.
paracasei strain expressing Listeria adhesion protein (Burkholder and Bhunia 2010;
Jagadeesan et al. 2010) developed by Koo et al. (Koo et al. 2012) had reduced L.
monocytogenes adhesion, invasion and translocation in Caco-2 cell culture model. The
recombinant probiotic bacterium expresses LAP, an essential virulence factor that aids in
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adhesion to and paracellular translocation of L. monocytogenes across intestinal epithelial
cells that are anchored to the cell wall. LAP interacts with the host Hsp60 (receptor) and
facilitates L. monocytogenes extraintestinal dissemination across the epithelial barrier
(Burkholder and Bhunia 2013; Kim and Bhunia 2013). LAP not only enhances probiotic
bacteria binding to the host GIT and attached to a L. monocytogenes receptor, but also
may allow the probiotic bacteria to be administered frequently to the host for enhanced
binding of the probiotic bacteria.

2.10.6.Viral pathogens
Norovirus (NoV) is the leading cause of foodborne and waterborne acute
gastroenteritis worldwide (Jianrong et al. 2012; Rodriguez-Lazaro et al. 2012; Rubio-delCampo et al. 2014). In the United States, it is responsible for an estimated 23 million
cases of gastroenteritis and 50,000 hospitalizations each year (Patel et al. 2009; Mattison
2011). The resulting symptoms of a NoV infection continue for 12-60 h and include
gastroenteritis, self-limiting diarrhea, vomiting, and, in some cases, dehydration and
death (Rubio-del-Campo et al. 2014). Recently, a recombinant probiotic Lactobacillus
paracasei (rLbp) secreting 3D8 single-chain variable fragment (3D8 scFv), an antinucleic
acid antibody which can penetrate a cell and hydrolyze DNA, has antiviral activity in
both in vitro RAW 264.7 cell culture models and in vivo mouse models (accepted model
for NoV) (Phuong Mai et al. 2015). Mice pretreated with rLbp secreting 3D8 scFv (3
administrations orally over 6 days) had a 20-fold reduction in mRNA expression of the
viral polymerase gene compared to mice pretreated with the empty vector rLbp; however,
no change in viral-associated cytokine levels were observed. This could be the result of
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the small number of oral administration of probiotic bacteria (Phuong Mai et al. 2015).
In a human study, fermented milk containing L. casei Shirota was given to patients
suffering from NoV infection. The treatment group had a decreased duration of fever and
gastrointestinal distress compared to the control group (Nagata et al. 2011)
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CHAPTER 3. RECOMBINANT LISTERIA ADHESION PROTEIN EXPRESSING
PROBIOTICS MITIGATE LISTERIA MONOCYTOGENES INFECTION IN
MICE
3.1 Introduction
Ubiquitous, opportunistic foodborne pathogen, Listeria monocytogenes is
responsible for listeriosis, a systemic infection in immunocompromised individuals and
premature birth, stillbirth, or abortion in pregnant women. To cause this severe systemic
infection and infect the fetuses of pregnant individuals, L. monocytogenes must survive
the harsh environment of the stomach and breach the intestinal epithelial barrier and host
innate defense to gain entry into the blood stream and access to successive organs and
tissues. L. monocytogenes has become a proficient human pathogen through expression
of a variety of virulence factors allowing it to evade host immune system, translocate
across barriers, and spread cell-to-cell (Marco et al. 1997; Hamon et al. 2006; Sleator et
al. 2009). Two well characterized mechanisms that L. monocytogenes employs to invade
and cross the gut barrier are, passive invasion through microfold (M) cells (Pron et al.
1998) and active invasion via virulence factor Internalin A (InlA) (Lecuit et al. 1999;
Lecuit et al. 2000; Lecuit et al. 2001). Bacterial InlA interacts host receptor E-cadherin
located on the basolateral side of the adherens junction (AJ), which is inaccessible to
luminal L. monocytogenes (Pizarro-Cerdá et al. 2012); however, there have been
proposed mechanisms suggesting that the InlA/E-cadherin interaction is possible during
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epithelial cell extrusion (Pentecost et al. 2006) or mucus exocytosis from goblet cells
(Nikitas et al. 2011).
InlA interaction with E-cadherin is highly host species specific and a single amino
acid substitution of Glu for Pro inhibits the interaction in mice and rats, as opposed to
humans (Lecuit et al. 1999); however, L. monocytogenes has been shown to cross the
intestinal epithelial barrier in these non-permisive species, suggesting that other
translocative mechanisms occur (Burkholder and Bhunia 2010; Ghanem et al. 2012). Our
lab has demonstrated that the moonlightling protein Listeria adhesion protein (LAP)
interacts with host moonlighting protein heat shock protein 60 (Hsp60) (Wampler et al.
2004) to adhere to the host intestinal epithelial cell and invade independent of InlA
(Burkholder and Bhunia 2010; Drolia et al. 2016). LAP is a 866 amino acid
housekeeping alcohol aldehyde dehydrogenase involved in bacterial metabolism
(Jagadeesan et al. 2010). LAP secretion is SecA2-dependent and it extracellularly binds
to bacterial cell wall (Burkholder and Bhunia 2010). Importantly, LAP expressed in
pathogenic L. monocytogenes shared homology with non-pathogenic LAP expressed in L.
innocua (Jagadeesan et al. 2010; Jagadeesan et al. 2011). Hsp60 is a incracellular
chaparone protein that is also found in the cell membrane of intestinal epithelial cells
(Wampler et al. 2004).
Currently the only mitigation stratagy endorsed by the CDC is, if
immunocompromised or pregnant avoid high risk foods such as ready-to-eat deli meats,
hotdogs, dairy products and produce such as cantalopes and apples. Despite these
restrictions, L. monocytogenes is still has a mortality rate of 20-30%, making it one of the
highest mortality foodborne, enteric pathogens (Voetsch et al. 2007). This suggests that
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new intervention methods are required. Pathogen interaction with the intestinal mucosa
is the first important interaction between pathogen and host (Finlay and Falkow 1997),
therefore, it would be prudent to investigate mitigation strategies focusing on this
interaction and subvert further pathogenesis. Probiotic have recently become an
attractive option for prophylactic treatment of enteric pathogens because they are able to
persist in the gastrointestinal tract and hold the possibility of direct or indirect inhibition
of enteric pathogens. One of the most common probiotic genera supplemented is
Lactobacillus, for its ability to colonize and persist in the gut, to enhance host gut
microbiome, influence the host immune system enhancing gut homeostasis), and to
enhance host gut barrier integrity (Amalaradjou and Bhunia 2012; Hill et al. 2014;
Sanders et al. 2014). However, these activities are unpredictable and highly strain
specific (Hill et al. 2014).
To enhance the efficacy of probiotic therapy and provide a target specific
mechanism of pathogen inhibition or neutralization, probiotics have been engirnnered to
express recombinant pathogen specific virulence factors or antimicrobial molecules to
increase efficacy of specific pathogen mitigation (Chang et al. 2003; Focareta et al. 2006;
Mohamadzadeh et al. 2010; Amalaradjou and Bhunia 2013). Following this template, we
investigated the efficacy of Lactobacillus casei ATCC 334 expressing cell wall anchored
LAP from either L. monocytogenes (pathogenic) or L. innocua (non-pathogenic). Here
we show that these probiotics are able to mitigate L. monocytogenes dissemination to
extraintestinal tissues, improve gut barrier function, and modulate host immune response
to protect >90% mice from infection.

54
3.2. Materials and Method
3.2.1 Bacterial strains, growth conditions, and inoculum preparation
All Listeria species were grown in tryptic soy broth containing 0.6% yeast extract
(TSBYE; Becton Dickinson, Sparks, MD) or Luria-Bertani broth (LB, 0.5% NaCl, 1%
tryptone peptone, and 0.5% yeast extract) at 37°C for 16 to 18 h. Probiotic bacteria were
cultured in deMan Rogosa Sharpe broth (MRS, Becton Dickinson) at 37°C for 18-20 h.
Lactobacillus casei ATCC 344 wild type (LbcWT) (a gift from Mike Miller, University
of Illinois, Urbana) was used as a host to express LAP from L. innocua (LbcLAPLin) and
L. monocytogenes (LbcLAPLm). To recover this strain from fecal and intestinal samples
during animal study, a vancomycin resistant strain of L. casei was selected by
sequentially culturing the bacterium in increasing concentrations of vancomycin (300
g/ml). LbcWT was grown under anaerobic conditions at 37°C. Recombinant L. casei
strains were grown under anaerobic conditions at 37°C with erythromycin (2 μg/mL).
LbcWT, LbcLAPLm, and LbcLAPLin probiotic supplement was prepared by
growing the probiotics overnight and pelleting them by centrifugation 8000 xg for 10
min. The probiotic pellet was washed with sterile water and pelleted again. The washed
probiotic pellets were resuspended in 30 ml of sterile water at a concentration of 9  109
cfu/ml and supplied to animals in the drinking water bottle. L. monocytogenes challenge
was prepared by pelleting an overnight grown culture by centrifugation at 8000 g for 3
min. The pelleted cells were washed in sterile PBS and pelleted again. Washed pellet
was resuspended in sterile PBS at a concentration of 4 108 cfu/100 μl.
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Table 3-1. Bacterial strains and culture conditions
Bacterial
strain

Media

Antibiotics

Aerobic/
Anaerobic

Time
(h)

Temperature

L.
monocytogenes
F4244

TSBYE,
TSAYE,
MOX

-

Aerobic

16-18

37oC

L. innocua
F4248

TSBYE,
TSAYE,
MOX

-

Aerobic

16-18

37oC

LbcWT

MRS,
MRSA

-

Anaerobic

12-14

37oC

LbcLAPLm

MRS,
MRSA

erythromycin
(2 μg/ml)

Anaerobic

12-14

37oC

erythromycin
MRS,
Anaerobic
12-14
37oC
MRSA
(2 μg/ml)
TSBYE, tryptic soy broth containing 0.6% yeast; TSAYE, tryptic soy agar containing
0.6% yeast extract; MOX, modified oxford agar; MRS, deMan Rogosa Sharpe broth;
MRSA, deMan Rogosa Sharpe agar
LbcLAPLin

3.2.2 Mouse bioassay
Female mice (A/J: 8-10 weeks of age; n=24) were purchased from Jackson
laboratories (Bar Harbor, Maine). The animal bioassay procedure was approved by the
Purdue University Animal Care and Use Committee (1201000595A003). Upon arrival,
mice (1/cage) were housed in cages that included nesting cotton for enrichment.
Shepherd's™ ALPHA-dri® (alpha cellulose) was used for bedding. Animals were
provided adlib feed (Rodent Diet 5001, LabDiet, Brentwood, MO) and sterile deionized
water, and acclimatized for 5 days before the experiment. A cycle of 12 h artificial light
and 12 h darkness was maintained. Relative humidity was 50-60% and temperature was
20-25°C. Mice were randomly assigned to eight different groups (Table 3-1).
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Table 3-2. Mouse grouping and treatments
Group number
Treatment
I
No Lbc
II
No Lbc + Lm
III
LbcWT
IV
LbcWT + Lm
V
LbcLAPLm
VI
LbcLAPLm + Lm
VII
LbcLAPLin
VIII
LbcLAPLin + Lm

No. of mice per group
6
3
3
3
3
3
3
3

Fresh preparations of probiotics were supplied daily through sterile deionized water at 9
 109 CFU/ml for 10 days (Fig 3-1). All mice consumed a minimum of 5 ml of
probiotics each day. Control animals received only sterile water. For challenge
experiment, mice received oral gavage of L. monocytogenes F4244 (WT) at a
concentration of 8.8  108 CFU/mouse using a feeding tube (Popper) and control mice
received PBS (Burkholder et al. 2009). Animals were observed for clinical signs of
infection, such as ruffled hair, movement and recumbence, and their feeding and drinking
habits.
Mice were euthanized by CO2 asphyxiation at 48 h pi, and intestine (duodenum,
jejunum and ileum), spleen, liver, kidney, lungs and blood from the heart via a cardiac
puncture were aseptically collected. Intestinal homogenates were frozen and stored at
-80oC the same day after enumeration for future cytokine quantification. Feces were
collected from each mouse from time of infection to sacrifice. Organs were homogenized
using a tissue homogenizer (Cole Parmer, Vernon Hills, IL) in 0.5 ml (blood), 4.5 ml
(spleen, kidney, lungs) or 9 ml (feces, intestine, liver) of PBS. MRS agar (Neogen,
Lansing, MI) containing vancomycin (300 g/ml) was used for enumeration of LbcWT,
and MRS agar containing erythromycin (2 g/ml) was used for bioengineered strains.
Modified Oxford medium (MOX; Neogen, Lansing, MI) was used for enumeration of
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microcentrifuge tubes (Fisher Scientific, Waltham, MA). Blood (50 -250 μl/animal) was
collected by cardiac puncture and stored in individual microcentrifuge tubes and sera was
obtained (section 3.3.4). Sera and urine were appropriately diluted and assayed for FD4
by measuring in a spectrophotometer as described (Condette et al. 2014).

3.2.5. Cytokine quantification by ELISA
Caco-2 monolayers (about 12 days of incubation) were grown in 12 well plates in
Hyclone High Glucose Dulbecco’s modified Eagle medium (DMEM) (GE) containing
10% fetal calf serum (GE). Probiotics were grown in MRS or MRS containing
erythromycin (2 μg/mL) for 12 h anaerobically at 37oC statically. Probiotic cultures were
pelleted by centrifugation at 8,000 xg for 5 min and washed with sterile PBS. Probiotics
were suspended in serum free Hyclone High Glucose DMEM (GE), introduced to the
monolayer at an MOE of 10:1 and incubated for 24 h. Non-adherent probiotics were
washed off the monolayers with buffered PBS. L. monocytogenes for challenge was
grown in TSBYE for 16 h and a 1% subculturein TSBYE was grown for 6 h to reach the
appropriate cell density of 108 cfu/ml. L. monocytogenes was pelleted by centrifugation
at 8,000 xg for 3 min, washed in 1 ml of sterile PBS, and resuspended in serum free
DMEM. The monolayers were challenged with L. monocytogenes at an MOE 10:1 or
LPS-free purified rLAP (1 mg/ml) for 1 h (See section 3.2.7). Culture supernatants were
collected and tested for IL-6 and TNF- content using sandwich ELISA kits (Raybiotech
ELH-IL6 and ELH-TNF-). Briefly, supernatants were applied to the manufacturer
supplied pre-coated 96 well ELISA plates (100 l/well) and incubated overnight (16 h).
Primary biotinylated antibodies specific to IL-6 or TNF- and streptavidin conjugated
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secondary antibodies were incubated for 1 h and 45 min, respectively, at room
temperature. Color was developed as instructed by the manufacturer (Raybiotech) using
TMB (100 l/well) incubated for 30 min at room temperature. Color development was
stopped by adding stopping solution (50 l/well), supplied in the kit. Color was
measured at wavelength 450 nm by an Epoch Microplate Reader (Biotek, Winooski, VT).
Mouse intestinal tissue homogenates were obtained from the mouse bioassay
samples that were frozen and were thawed overnight at 4oC. They were assayed for IL-6
and TNF- quantification using mouse specific sandwich ELISA kits (Cat No. ELMTNF- and ELM-IL6-CL, RayBiotech, Norcross, GA). Briefly, ileal tissue homogenates
from each animal were applied to the manufacturer supplied pre-coated 96 well ELISA
plates (100 l/well) and were incubated overnight (16 h) at 4oC. Primary biotinylated
antibodies specific to IL-6 or TNF- and streptavidin conjugated secondary antibodies
were incubated for 1 h and 45 min, respectively, at room temperature. Color was
developed as instructed by the manufacturer (Raybiotech) using TMB (100 l/well)
incubated for 30 min at room temperature. Color development was stopped by adding
stopping solution (50 l/well), supplied in kit. Color was measured at wavelength 450
nm using an Epoch Microplate Reader (Biotek, Winooski, VT).

3.2.6. Cytokine detection by semi-quantitative array
Pooled sera from each group was used for a semi-quantitative cytokine array (Cat.
No. AAM-CYT-1, RayBiotech, Norcross, GA). Immunoblotting was performed as per
manufacturer instructions, and the reaction intensity was quantified using the NIH ImageJ
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software. The data were normalized to array-specific positive controls and then
expressed as mean fold change.

3.2.7. Short chain fatty acid quantification
Fecal pellets (100mg) were homogenized in 900μl of water and 1.4mm ceramic
beads using a Precellys 24 homogenizer (Bertin Instruments, Rockville, MD). The
homogenates were labeled with regular aniline (12C6), and external SCFA standard
solution (10mg/ml of acetic acid, propionic acid, and butyric acid) was labeled with
aniline-13C6 using N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride
(2mg per sample). Crotonic acid (final 0.1mg/ml) was used as an internal standard. The
labeling mixture was incubated for 2h, and triethylamine was added to stop the labeling
reaction. Samples and standard reaction solution were mixed (1:1) and analyzed with an
Agilent 6460 Triple Quad LC/MS System (Agilent Technologies, Santa Clara, CA).

3.2.8. Seroconversion of LAP
Recombinant LAP (rLAP) was purified using Ni affinity chromatography (See
method in Appendix A) from E. coli BL21 or ClearColi (Lucigen) and separated by SDSPAGE (7.5% Acrylamide). The protein was electrically transferred to hydrophobic
membrane, Immobilon-P membrane (Millipore, Billerica, MA). Equal parts of pooled
sera from each treatment group were used to immunoprobe the membrane for 16 h at 4oC.
Horseradish peroxidase conjugated anti-mouse secondary antibody (Cat. No. AP308P,
Sigma) was used. The presence of anti-LAP antibodies was detected using the

61
chemiluminescence substrate LumiGLO (Cell Signaling Technology, Danvers, MA) with
a chemiluminescence detection system (Chemidoc XRS, Bio-Rad). Purified rLAP was
used as control in each blot.

3.2.9.

Interaction between probiotics and L. monocytogenes and immunomagnetic
separation of Listeria

L. monocytogenes F4244, L. innocua F4248, LbcWT, LbcLAPLm, and LbcLAPLin
were cultured for 16-18 h at 37oC in TSBYE, MRS, or MRS supplemented with 2 μg/ml
erythromycin broth, respectively (see section 3.2.1). All cultures were pelleted by
centrifugation at 8000 xg for 3 min and washed with sterile PBS. All cellular
concentrations were serially diluted to obtain a cell concentration of 106 cfu/ml. L.
monocytogenes or L. innocua were allowed to interact with the individual probiotic
strains (LbcWT, LbcLAPLm, or LbcLAPLin) at a 1:1 concentration in sterile PBS for 1 h at
room temperature with constant agitation on Lab Doctor Revolver (MidSci, Valley Park,
MO). Anti-Listerial magnetic Dynabeads (Cat. No. 71006, Thermofischer Scientific)
were used to capture and separate L. monocytogenes and L. innocua from unbound
probiotics. Briefly, 20 μl/ml of bead slurry was added to the bacterial mixtures and
allowed to interact for 10 min at room temperature with constant agitation. Beads were
magnetically separated and washed with sterile PBS-T (0.1%) 3 times (10 min each
wash) with constant agitation. Beads were serially diluted and plated on MOX (Neogen)
and MRS agar (BD) for enumeration of Listeria and probiotics, respectively.
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3.3.2 Recombinant Lactobacillus casei expressing non-pathogenic LAP reduced Lm
infection
Animals (n=30) were sacrificed 48 h post infection (pi). L. monocytogenes counts
in the liver, spleen, MLN, kidneys, blood, intestine, and lungs were determined (Fig. 3-4,
b-h). Generally, depending on the tissues or organs, the LbcWT feeding resulted in a
meager reduction of L. monocytogenes counts of only 0-1 log cfu/mouse. Remarkably,
the recombinant probiotics (LbcLAPLin or LbcLAPLm) supplied mice showed a reduction
of L. monocytogenes counts by 3.5-5 log (up to 99.999%) 48 h pi in liver and spleen (Fig.
3-4, b, c). L. monocytogenes was undetectable in blood and the kidney of recombinant
probiotic-fed mice (Fig. 3-4, f, h). Furthermore, in the recombinant probiotic -fed
animals, L. monocytogenes was undetectable from liver or spleen from 25-50% of the
mice while L. monocytogenes was isolated from all LbcWT–fed animals (n=3-6). No
background Listeria were detected from mice that received only the probiotics or no
probiotics at all. Collectively, these data demonstrate that recombinant probiotic were
maintained in the intestine of mice and protected mice from systemic L. monocytogenes
infection.
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Short chain fatty acids (SCFAs), especially butyrate, are also known to maintain
tight junction integrity (Elamin et al. 2013) and regulate inflammation (Maslowski et al.
2009; Tremaroli and Backhed 2012; Kim et al. 2013). Therefore, we analyzed SCFAs in
the feces of mice collected on day 0 and day 12 (day of sacrifice) of probiotic feeding.
Data show that, in general, all three SCFAs (acetate, propionate and butyrate) levels were
substantially lower in animals that did not receive any probiotics, but were challenged
with L. monocytogenes (Fig 3-6). In contrast, SCFAs were maintained at constant levels
in the animals that were fed with either LbcWT or recombinant probiotics with or without
L. monocytogenes challenge, similar to the control animals that did not receive any
treatments. These data show that L. monocytogenes alone was able to alter metabolic
activity of gut microbes resulting in overall reduced levels of SCFA synthesis while the
probiotics-fed mice had the ability to attenuate such negative effect, thus possibly playing
a role in preventing L. monocytogenes-induced epithelial barrier dysfunction.
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To assess the state of systemic immune response, levels of several cytokines in
the pooled sera from the three animals within each treatment group were analyzed using a
semi-quantitative immunoblot array). Data show a very high level of IL-6 (interleukin 6)
and MCP-1 (monocyte chemoattractant protein 1) in the sera in animals that were
infected with L. monocytogenes without any probiotics; however, probiotics (LbcWT,
LbcLAPLm, LbcLAPLin) exposure was able to dampen these two cytokine levels in the
sera of L. monocytogenes infected mice (Fig 3-8). In contrast, the level of G-CSF
(granulocyte colony stimulating factor) was very high in sera after L. monocytogenes
challenge, irrespective of the probiotics used. Serum TNF- level was undetectable
irrespective of the treatments. This may be an artifact of the sensitivity of the cytokine
array; however, as previously stated, intestinal TNF- levels were reduced in concert
with probiotic administration.
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pregnant mothers and their fetuses (Kirk et al. 2015). L. monocytogenes also contributes
to a costly economic burden. Currently, there are no medically preventative treatments
for these high-risk individuals and they are subject to avoidance strategies, such as not
consuming high-risk foods including ready-to-eat deli meats, soft cheeses, etc. Probiotics
offer attractive and cost effective platform to deliver preventative relief to these people;
however, due to the unpredictable and strain-specific nature of probiotic supplementation,
targeting specific pathogens proves ineffective. To address these shortcomings, many
studies have been conducted measuring the efficacy of recombinant probiotics expressing
a pathogenic virulence factor, antimicrobial agents such as bacteriocins, or host immune
proteins such as anti-inflammatory IL-10 to offer target specific intervention
(Amalaradjou and Bhunia 2012; Koo et al. 2012; Volzing et al. 2013). These target
specific enhancements to probiotic supplementation complement the health-positive
benefits that the native probiotic strain confer, such as enhanced barrier function
(Salminen et al. 2010; Cho et al. 2014), host immune modulation, short chain fatty acid
production through carbohydrate fermentation (Ng et al. 2009; Ng et al. 2013), increased
intestinal mucus production (Williams 2010; Shen-Shih and Tzu-Ming 2012), and safety
(Amalaradjou and Bhunia 2012; Amalaradjou and Bhunia 2013).
The probiotic intervention of Listeria has been generally ineffective (Culligan et al.
2009; Koo et al. 2012), so to address this ineffectiveness we have developed a probiotic
that expresses the LAP to prevent L. monocytogenes from breaching the intestinal barrier
and dissemination to extraintestinal tissues. We have shown that LAP has significant
implications regarding L. monocytogenes adhesion and paracellular invasion of intestinal
epithelial cells (Burkholder et al. 2009). LAP is a housekeeping enzyme that moonlights
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as a SecA2 secreted bacterial cell membrane adhesion protein (Burkholder and Bhunia
2009); however, LAP lacks a leader peptide and must bind to itself via interaction with an
unknown cell wall molecule. LAP from pathogenic L. monocytogenes shares 99.9%
sequence homology (Amalaradjou et al.in preparation) with LAP from non-pathogenic L.
innocua, yet LAP from L. innocua cannot re-associate with the bacterial cell wall once
secreted (Jagadeesan et al. 2010). This inability of L. innocua to translocate through
paracellular route plays a significant role in the failure of it to cause infection
(Burkholder and Bhunia 2010; Burkholder and Bhunia 2013).
We have asked the questions, can the LAP expressing recombinant probiotics
prevent listeriosis in Listeria sensitive A/J mice, and if so, due to the sequence homology
between pathogenic and non-pathogenic LAP, can a non-pathogenic LAP expressing
probiotic prevent listeriosis as efficiently a pathogenic LAP. We found that both
recombinant probiotics, LbcLAPLm and LbcLAPLin were able to protect the mice against
L. monocytogenes by a factor of up to 5 log, while the LbcWT strain provided a little or
no protection at all. Mice supplied with the recombinant probiotics showed no clinical
signs of listeriosis post infection. In contrast, the LbcWT supplied and challenged mice
were hunched, lethargic, unresponsive, and had a 17% reduction in body weight over 48
h, showing clear clinical signs of infection. Mice provided with recombinant probiotics
continued to eat and drink post infection, while mice provided with LbcWT or no
probiotics and challenged did not eat or drink post infection.
Taken together, data presented here suggest three possible mechanisms by which the
recombinant probiotics subvert pathogen extracellular dissemination and infection: (i)
Enhancement of intestinal barrier function, (ii) Enhancement or “priming” of the host
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immune system to aid in rapid clearance of the pathogen if it can breach the intestinal
barrier, and (iii) Direct interaction and binding of L. monocytogenes thus inhibiting the
pathogen interaction with host epithelial cells.
Maintenance of the epithelial junction proteins occludin and claudin is integral to
intestinal barrier function (Pagnini et al. 2010; Zhou et al. 2010). In this study we
observed that recombinant probiotic fed mice that were then challenged by L.
monocytogenes maintained the same gut permeability as unchallenged mice, while the
LcbWT-fed and Lm challenged mice showed an increase in gut permeability, suggesting
that the recombinant probiotics helped maintain gut integrity and mitigated L.
monocytogenes induced gut permeability, and bacterial paracellular translocation.
Another factor that impacts gut barrier integrity and homeostasis are SCFA (Hamer et al.
2008). SCFA, especially butyrate are the primary source of metabolic energy for
colonocytes and, as such aids in cellular performance (Plöger et al. 2012). Moreover,
SCFA can promote resistance to experimentally derived colitis (Cresci et al. 2013;
Leonel et al. 2013), suggesting its importance in barrier integrity. Here we found that L.
monocytogenes reduced colonic SCFA content and interestingly, probiotic-fed groups
maintained total SCFA content. We suspect that the change in SCFA content due to L.
monocytogenes is due to disruption of the gut microbiome; however, further studies ae
needed to fully elucidate this difference and its impact on microbiome versus probiotic
supplementation derived SCFA production. It is important to note that these mice also
stopped consuming feed pellets, which could also account for the change in SCFA
content.
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Immune modulation by probiotics has been shown to occur through marginal
stimulation of intestinal TNF and subsequent NF-B activation resulting in enhanced
innate immune function without any detrimental inflammatory responses and aiding in
gut homeostasis (Pagnini et al. 2010; Nagpal et al. 2012; Ng et al. 2013). Previous in
vitro studies using RAW264.7 macrophages exposed to cell wall extracts of
Bifidobacterium adolescentis, B. longum, and Lactobacillus salivarius Ren enhanced
phagocytic activity via increased production of IL-6 and TNF- (Zhu et al., 2011). Oral
gavage of mice with L. acidophilus and B. bifidum showed increased reactive oxygen
intermediates production and enhanced phagocytic activity in macrophages (Deepti and
Vinod 2014). Long-term consumption of certain probiotics has shown to enhance innate
immunity and production of IL-1, IL-6, IL-10, IL-12, IL-18, INF-, and TNF- by
monocytes and dendritic cells (Cross 2002; Niers et al. 2005). L. monocytogenes
challenge induced high levels of intestinal pro-inflammatory TNF- and IL-6 as well as
IL-6 in serum, suggesting a systemic infection. Recombinant probiotic fed groups proved
to mitigate local TNF- and IL-6 expression, while LbcWT did not.
In our previous report, LAP induced IL-6 and TNF- production during L.
monocytogenes infection through activation of NF-B (Drolia et al. in preparation), but in
this study, recombinant probiotics expressing LAP were able to dampen L.
monocytogenes-mediated proinflammatory cytokine production despite moderate
activation of NF-B. This suggests, perhaps that recombinant probiotics helped maintain
epithelial immune homeostasis thus was able to counteract L. monocytogenes mediated
inflammatory response. During innate immunity, monocytes secrete IL-6 when
stimulated by pathogen-associated molecular patterns (PAMPS) on specific pathogens
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that are recognized by pattern recognition receptors (PRR) including toll-like receptors
(TLRs) similar to LAP-Hsp60 interaction (Drolia et al., in Preparation). This suggests
that the recombinant probiotics can modulate innate immune response and subsequent
inflammation through either direct or indirect manipulation of pro-inflammatory
cytokines.
SCFA are also known to modulate host immune response by inducing IL-10 and
IFN- secretion (Kurita-Ochiai et al. 1995) and induction of Treg cell generation
(Furusawa et al. 2013) resulting in a reduction of inflammation. We suspect that the
maintenance of SCFA in intestinal content contributes to the probiotic modulation of the
innate immune system.
Probiotics have been shown to enhance the mucosal intestinal immune system.
Gut microbiota have been shown to interact with gut-associated lymphoid tissue (GALT)
and B cells, and induce secretion of antibodies (Peterson et al. 2007)). This is an
important part of the maintenance of intestinal homeostasis. A study in chickens showed
that probiotic-supplemented chickens and immunized with sheep red blood cells had
higher specific serum antibody titer than non-probiotic supplemented groups (Haghighi et
al. 2005). Similarly, we also found that the recombinant probiotics were possibly able to
enhance the adaptive immune response by inducing anti-listerial antibodies in serum of
challenged animals. Interestingly, we did not see anti-LAP serum antibodies in
unchallenged animals supplied with recombinant probiotics, suggesting that the
recombinant probiotics do not translocate across the intestinal barrier and promote B-cell
secretion of antibodies against the probiotic itself; however, they can play a role in
systemic immune response to L. monocytogenes infection. This may enhance adaptive
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immune response against L. monocytogenes resulting in faster and more efficient
clearance of bacteria that do translocate across the intestinal barrier.
Typically, direct probiotic inhibition of a pathogen is described by competitive
exclusion of the pathogen receptor (Amalaradjou and Bhunia 2013). However, it is
unlikely that the supplemented probiotic can penetrate the established gut microbiota and
the loosely and tightly adherent mucus layers to interact directly with the host epithelial
Hsp60 and competitively inhibit L. monocytogenes, rather it appears that the probiotic
itself may be binding the pathogen. We demonstrated that the recombinant probiotics
were able to bind L. monocytogenes 2 log more than LbcWT, while they showed no
increase in the binding of L. innocua. Likewise, it is established that SCFA, especially
acetate and propionate can directly inhibit L. monocytogenes growth (Julotok et al. 2009);
therefore, the enhancement of SCFA content in recombinant probiotic-fed and Lmchallenged groups could directly inhibit the pathogen.
In conclusion, we demonstrated that recombinant LAP expressing probiotics,
especially the non-pathogenic LAP expressing probiotic were able to reduce translocation
and dissemination of L. monocytogenes, enhance gut barrier function, and modulate host
immune response. We suspect that a combination of probiotic mechanisms working in
concert including direct binding of the pathogen and enhancement of cell junction
proteins and inflammation are responsible; however, whether the recombinant probiotics
are directly affecting these changes or indirectly through maintenance of the host gut
microbiome has yet to be elucidated.
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CHAPTER 4. LISTERIA ADHESION PROTEIN EXPRESSING PROBIOTICS
REDUCE EXTRAINTESTIAL DISSEMINATION OF LISTERIA
MONOCYTOGENES IN PREGNANT GUINEA PIGS

4.1

Introduction

Listeria monocytogenes is a Gram-positive bacterium, ubiquitous in nature and is
associated with foodborne illness transmitted by produce, processed meat and dairy
products. L. monocytogenes is a rare enteric pathogen because it is generally not
associated with gastric distress, rather it causes a severe invasive systemic infection in
high-risk individuals such as pregnant women, newborns, the elderly, and
immunocompromised individuals (Swaminathan and Gerner-Smidt 2007). While L.
monocytogenes is associated with a relatively low morbidity when compared to other
enteric pathogens such as Salmonella, the mortality rate is very high (20-30%) (Voetsch
et al. 2007). Kirk et al (Kirk et al. 2015) estimated that there were 14,169 cases of L.
monocytogenes infections leading to 3,175 deaths globally in 2010. This equates to a
staggering 22.4% mortality rate.
To cause systemic infection, Listeria monocytogenes must escape the GI tract and
disseminate to extra intestinal tissues. L. monocytogenes has multiple mechanism to
facilitate this, including the well characterized interaction of Lm virulence factor InlA
and host E-cadherin (Lecuit et al. 1999; Yu et al. 2012) and passive translocation through
microfold (M) cells overlaying the Peyer’s patch (Lelouard et al. 2012).
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Alternatively, L. monocytogenes secretes the Listeria Adhesion Protein (LAP), a
bifunctional house-keeping alcohol acetaldehyde dehydrogenase. Our lab has implicated
LAP in Lm adhesion to epithelial cells via interaction with host epithelial heat shock
protein 60 (Hsp60) (Wampler et al. 2004), a moonlighting chaperone protein (Henderson
et al. 2013), positively influencing Internalin-independent paracellular translocation
(Burkholder and Bhunia 2010; Burkholder and Bhunia 2013). Non-pathogenic species of
Listeria also express the LAP protein. LAP from L. monocytogenes F4244 (pathogen)
and Listeria innocua F4248 (non-pathogen) have near complete homology (99.4%)
(Jagadeesan et al. 2010). Regardless of the mechanism, once L. monocytogenes has
escaped the GI tract it disseminates to the mesenteric lymph nodes (MLN), liver, spleen,
blood, and can eventually penetrate both the blood-brain and feto-placental barriers
(Burkholder et al. 2009; Ribet and Cossart 2015). Prevention of L. monocytogenes
translocation across the intestinal epithelial barrier would circumvent L. monocytogenes’
ability to cause systemic infection.
Guinea pigs have classically been used as the model for pregnancy related
pathogenicity because of the similarity in placental structure compared to humans (Leiser
and Kaufmann 1994; Bakardjiev et al. 2004). Additionally, the InlA/E-cadherin
interaction is host species-specific due to a substitution at the amino acid sequence
position 16 at which Pro is substituted by Glu in the host species' E-cadherin. InlA may
have low affinity for mouse or rat E-cadherin but interacts strongly with the E-cadherin
of permissive hosts, such as humans and guinea pigs (Lecuit et al. 1999). Studies using
transgenic mice expressing “humanized” E-cadherin (Disson et al. 2008) or murinized
InlA (InlAm) (Wollert et al. 2007; Ghanem et al. 2012) have indicated that L.

82
monocytogenes may use alternate routes to translocate across the gut mucosa. So, while
mice have been deemed an acceptable model for non-pregnant L. monocytogenes
infectious studies, they are unsuitable for pregnancy related studies.
Probiotics have the ability to colonize the GI tract and positively benefit the host
in several ways, thus making them an attractive prospect for therapy against enteric
pathogens. Because of their ability to specifically enhance gut health and function,
probiotics may be considered to be a functional food (Nagpal et al. 2012). Probiotics are
typically nonpathogenic microorganisms that promote health benefits when administered
in clinically appropriate dosing. The most common probiotics are Lactobacillus and
Bifidobacterium. To be considered a probiotic, a microorganism must exert benefits in
three ways: (i) Provide the host with organic acids (short chain fatty acids) through
anaerobic fermentation of carbohydrates that can be positively utilized by the host. There
has been a wealth of recent studies investigating the wide reach of these fermentation
products, suggesting that they play a major role in brain function and cognition. (ii)
Stimulate or prime the host immune system, without causing inflammation within the
gastrointestinal tract (GIT). (iii) Exclude pathogens in the GIT from causing disease by
outcompeting them for the limited resources and space (Stecher and Hardt 2011). In
general, probiotics are known to prevent/alleviate chronic inflammatory bowel disease,
colorectal cancer, metabolic disorders, allergic response, obesity, and osteoporosis
(Azcarate-Peril et al. 2011; Ly et al. 2011; Amalaradjou and Bhunia 2012; Cate et al.
2015; Kim et al. 2016).
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One major drawback of probiotics as vaccine is that their protection is
unpredictable, making it a difficult platform for target specific activity. We have
bioengineered probiotics expressing the LAP, which enhances the specificity of the
protection. Previously our research group has demonstrated that recombinant LAPproducing probiotics reduce dissemination to extraintestinal tissues 3-5 log in healthy mice,
suggesting that they are an appropriate protective vaccine against listeriosis. In this study,
we showed that recombinant probiotics, especially expressing LAP from Listeria innocua
can reduce dissemination to extraintestinal, placental and fetal tissues in pregnant guinea
pigs, help maintain intestinal SCFA content, modulate host cytokine expression, and confer
general health benefits associated with probiotic therapy.

4.2

Materials and Methods

4.2.1 Bacterial cultures and growth conditions
All bacteria used were grown under the same conditions as previously described
and listed in (Table 4-1) (Amalaradjou et al., in preparation). The construction of the
recombinant probiotic strains LbcLAPLm and LbcLAPLin has been previously described
(Koo et al. 2012). Briefly, L. monocytogenes F4244 (serovar 4b) was grown in tryptic
soy broth containing 0.5% yeast extract (TSBYE; Becton Dickinson, Sparks, MD) at
37°C for 16 to 18 h. Wild type probiotic bacteria were cultured in deMan Rogosa Sharpe
broth (MRS, Becton Dickinson) or plated on MRS agar and grown at 37°C for 12-14 h.
Lactobacillus casei ATCC 344 wild type (LbcWT) (a gift from Mike Miller, University
of Illinois, Urbana) was used as a host to express LAP from L. innocua and L.
monocytogenes. Recombinant L. casei expressing LAP from L. monocytogenes
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(LbcLAPLm) and from L. innocua (LbcLAPin) were grown in MRS broth containing
erythromycin (2 μg/ml) at 37oC for 12-14 h or plated on MRS agar containing
erythromycin (2 μg/ml).
Table 4-1. Bacterial growth requirements
Bacterial
strain

Media

Antibiotics

Aerobic/
Anaerobic

Time
(h)

Temperature

L.
monocytogenes
F4244

TSBYE,
TSAYE,
MOX

-

Aerobic

16-18

37oC

LbcWT

MRS,
MRSA

-

Anaerobic

12-14

37oC

LbcLAPLm

MRS,
MRSA

erythromycin
(2 μg/ml)

Anaerobic

12-14

37oC

erythromycin
MRS,
Anaerobic
12-14
37oC
MRSA
(2 μg/ml)
TSBYE, tryptic soy broth containing 0.6% yeast; TSAYE, tryptic soy agar containing
0.6% yeast extract; MOX, modified oxford agar; MRS, deMan Rogosa Sharpe broth;
MRSA, deMan Rogosa Sharpe agar. Recombinant probiotic strains (LbcLAPLm and
LbcLAPLin) were developed by Amalaradjou et al. (manuscript in preparation).
LbcLAPLin

4.2.2 Pregnant guinea pig bioassay
The animal bioassay procedure was approved by the Purdue University Animal
Care and Use Committee (1201000595A003). Pregnant Dunkin-Hartley guinea pigs were
purchased from Elm Hill Labs (Chemsford, MA) on their 24-28th gestational day (Fig 41). Upon arrival, Guinea pigs (1/cage) were housed in a cage with a hut and chew toy for
enrichment. Cedar shavings was used for bedding. Animals were provided adlib feed
(Guinea Pig Diet 5025, LabDiet, Brentwood, MO) and sterile deionized water, and
acclimatized for 5 days before the experiment. A cycle of 12 h artificial light and 12 h
darkness was maintained. Relative humidity was 50-60% and temperature was 20-25°C.
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Guinea pigs were prescreened for listerial infection. One day after arrival animal fecal
pellets were screened for preexisting L. monocytogenes infection by homogenizing 1 g of
fecal pellets in 10 ml of University of Vermont (UVM, BD) broth and pre-enriched by
incubating at 37oC for 24 h (pre-enrichment). One ml of pre-enriched sample was
enriched for L. monocytogenes in 10 ml of Frasier Broth (BD) at 37oC for 24 h, and
plated on Modified Oxford (MOX) agar plates. Any colonies suspected of being L.
monocytogenes were confirmed by PCR. Guinea pigs were randomly assigned into five
groups and experiments were carried out in two separate trials performed in 2-weeks
interval (Table 4-2).
Table 4-2. Pregnant guinea pig grouping scheme
Group

Treatment

I
II
III
IV
V

No Lbc (Negative Control)
No Lbc + Lm
LbcWT + Lm
LbcLAPLm + Lm
LbcLAPLin + Lm

Guinea Pigs (n)
Trial 1 Trial 2
Total
2
2
4
3
3
6
3
4
7
3
3
6
4
4
8

Probiotics (9  109 cfu/ml, 50 ml/animal) were prepared fresh daily by pelleting
an overnight probiotic culture by centrifugation (8000 g for 10 min) and washing the
cells in sterile water. Washed cells were then pelleted again (8000 g for 10 min) and
resuspended in 50 ml of sterile water. Probiotics were supplied to guinea pigs through a
bottle daily for 17 days (9  109cfu/ml). All guinea pigs consumed a minimum of 35 ml
of water per day. Guinea pigs that refused to consume food, water, or both were syringe
fed needed sustenance three times daily. For L. monocytogenes challenge, overnight
grown L. monocytogenes was mixed with sterile cream sweetened with Splenda (5
mg/ml) at a concentration 9  108 cfu/ 2 ml for trial 1 and 2.5  109 cfu/ 2 ml for trial 2.
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To desensitize guinea pigs to the stress of syringe feeding, for the three days preceding
the challenge, animals were syringe fed 2 ml of sweetened cream. On day 14, animals
were syringe fed a sub-clinical dose, 9 108 cfu/animal for trial 1 and 2.5  109
cfu/animal for trial 2 of L. monocytogenes F4244 prepared in 2 ml of sweetened cream.
Animals were sacrificed 72 h post challenge via barbiturate overdose and maternal
(intestines, liver, spleen, mesenteric lymph nodes (MLN), kidney, lungs, placenta and
blood) and fetal tissues (liver and brain) were collected. Blood was collected post
sacrifice using a cardiac puncture. Pieces of organs (approximately 1 g) were
homogenized in 9 ml of PBS using a tissue homogenizer (Cole Parmer, Vernon Hills, IL)
or stomached using a stomacher in sterile PBS. Samples were serially diluted in sterile
PBS and plated on MRS agar (for Lbc enumeration) and TSBYE agar containing MOX
Listeria supplement (Neogen) (for L. monocytogenes enumeration) the same day. When
no L. monocytogenes colonies were observed on MOX plates, samples (500 μl of tissue
homogenates) were immediately transferred to 3 ml Frasier Broth (BD) and incubated at
37oC for 24 h. The positive Frasier Broth cultures were determined by the presence of
black pigment in the broth and were plated on MOX plates (Neogen). Three colonies per
MOX plate were confirmed as L. monocytogenes by amplifying prfA gene by
conventional PCR (see section 4.3.3 for protocol).
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done using a thermocycler (GeneAmp PCR System 9700, Applied Biosystems) as
follows in table 4-3.
Table 4-3. PCR conditions for amplification of prfA
Temperature (oC)
Time
Initial Denaturation
95
5 min
Cycles
Denaturation
95
60 s
Annealing
54
60 s
Extension
72
90 s
Final Extension
72
10 min

Cycles
1
30

1

The amplified DNA was resolved in 1.2% agarose gel and visualized by ethidium
bromide staining with a ChemiDoc XRS gel documentation system (Bio-Rad).

4.2.4. Serum cytokine quantification
Serum IL-6, TNF-, and TGF-1 were quantified using RayBio Human ELISA
Kits ELH-IL6, ELH-TNFa, and ELH-TGFb1 (RayBiotech, Norcross, GA), respectively,
using manufacturer instructions. Briefly, TGF-1 required activation before
quantification which was accomplished by adding 0.1 ml of 2.5 N Acetic acid/10 M Urea
per 0.1 ml of serum, incubated at room temperature for 10 min and 0.1 ml 2.7N
NaOH/1M HEPES per 0.1 ml of serum to neutralize acidified serum. Samples were used
immediately. IL-6 and TNF- do not require activation. Serum samples were diluted
two fold with dilution buffer B (supplied in kit) and 100 μl of diluted serum was added to
ELISA wells. They were incubated at 4oC gently shaking for 16 h. Each ELISA plate
was immunoprobed with their respective biotinylated primary antibodies and at
Streptavidin-Horse Radish Peroxidase conjugated secondary antibody for 1 h and 45 min,
respectively. Plates were developed using 100 μl TMB solution/well and incubated for
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30 min at room temperature. Stop solution (50 ul/well) was added and color
development was measured at wavelength 450 nm using an Eposh Microplate
Spectrophotometer (Biotek, Winooski, VT). Cytokines were quantified using a standard
curve as directed by the manufacturer.

4.2.5. Guinea pig serum cytokine array
Within each treatment group, 50 μl of serum from each animal were pooled and 1
ml of the mixed pooled sera was applied to semi-quantitative human inflammatory
cytokine array membranes (AAH-CYT-1, Raybiotech Inc., Norcross, GA) overnight at
4oC. Human arrays were used because guinea pig specific arrays are not available.
Moreover, guinea pigs have high homology with humans. Immunoblotting was
performed as per manufacturer instructions and the reaction intensity was quantified
using NIH ImageJ software. The background was subtracted from each datum point;
they were normalized to array-specific positive controls and expressed as mean fold
change.

4.2.6. Short chain fatty acid quantification from guinea pig feces
The sort chain fatty acid (SCFA) content of feces and serum was performed at
The Metabolite Profiling Facility, Bindley Bioscience Center at Purdue University. Fecal
pellets (100mg/animal) were pooled within each group and homogenized in 900μl of
water and 1.4mm ceramic beads per 100 mg of fecal pellets using a Precellys 24
homogenizer. Sera (100 μl/animal) were pooled within each treatment group and mixed
by pipetting. The pooled fecal homogenates or serum were labeled with regular aniline
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(12C6), and external SCFA standard solution (10mg/ml of acetic acid, propionic acid, and
butyric acid) was labeled with aniline-13C6 using N-(3-Dimethylaminopropyl)-N-ethyl
carbodiimide hydrochloride (2mg per sample). Crotonic acid (final 0.1mg/ml) was used
as an internal standard. The labeling mixture was incubated for 2h, and triethylamine was
added to stop the labeling reaction. Samples and standard reaction solutions were mixed
(1:1) and analyzed with an Agilent 6460 Triple Quad LC/MS System (Agilent
Technologies, Santa Clara, CA). Fecal content was analyzed at day 0 and day 17
(sacrifice) and SCFA were quantified (μg/mg). Fecal SCFA data was represented in fold
change between day 0 and day 17. Endpoint serum (day 17) was analyzed for SCFA
content.

4.2.7. Seroconversion of LAP
Serum was pooled within each treatment group and antibodies against LAP and
probiotics were analyzed using Western blot. Recombinant LAP was purified from E.
coli BL21 or ClearColi (Lucigen) using a Ni-affinity column. Recombinant LAP (5
μg/well) was separated using SDS-PAGE (7.5% polyacrylamide) and transferred to
hydrophobic, Immobilon-P membrane (Millipore, Billerica, MA). Membranes were
immunoprobed using 100 μl of pooled sera diluted in sterile PBS (1:50) and incubated at
4oC overnight (12-16 h). A secondary, anti-guinea pig antibody conjugated with
Horseradish Peroxidase (Cat. No. A18769, Life Technologies), 0.5 μg/ml was used and
developed using 3,3'-Diaminobenzidine (DAB) or LumiGLOW chemiluminescent
substrate (Cell Signaling).
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4.2.8. Quantification of total serum cholesterol
Total serum cholesterol was quantified using Amplex Red Cholesterol Assay Kit
(Thermo Fischer Scientific) by the manufacturer’s instructions. Briefly, 5 μl of serum
from each guinea pig was diluted tenfold using reaction buffer (supplied in kit) for a total
volume of 50 μl. The diluted serum was applied to a 96 well black microtiter plate (Cat.
No. 437111, ThermoScientific) and 300 μl Amplex Red Reagent (supplied in kit) was
added to each well. The samples were incubated statically at 37oC for 30 min and
flourometric measurements were taken using excitation wavelength of 544 nm and
emission wavelength of 590 nm using a Spectramax Gemini EM (Molecular Devices,
Sunnyvale, CA. Total cholesterol quantities were calculated by manufacturer’s
instructions.

4.2.9. Histopathology
Guinea pig tissues were fixed in 10% neutral buffered formalin and embedded in
paraffin. Sections (5 m thick) were stained with haematoxylin and eosin according to
standard methods. Microscopic examination was performed by a board-certified
veterinary pathologist and the interpretation was based on standard histopathological
morphology. The pathologist was blinded to the treatment groups, and compared ileal,
liver and lymph node sections to controls. To determine the extent of guinea pig ileal
lesions, a semi-quantitative method was used that included the amount of inflammatory
infiltrate and percentage of goblet cells comprising the villous epithelium. Similarly,
guinea pig liver and mesenteric lymph node were evaluated based on extent of
parenchymal necrosis and infiltrative inflammation. A histomorphological scale for
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assessing inflammation in the lamina propria of the mucosa is provided as follows: 3,
marked amounts (sheets of granulocytes expanding the width of the villous tip); 2,
moderate amounts (sheets of granulocytes at the base of the villous); 1, mild amounts
(multifocal scattering); and 0, none seen. To estimate percentage of goblet cells,
following scale was used: 3, 50% or greater; 2, 25-50%; 1, 11-25%; and 0, <10%. The
higher the score, the more likely there is infection in the tissues.

4.3

Results

4.3.1 Recombinant probiotics persist only in the GIT
For this probiotic vaccine to be an effective preventative against L.
monocytogenes infection and possible damage to the fetus, it is imperative that the
probiotic can persist in the gastrointestinal tract. To assess probiotic colonization of the
gut, fecal samples from each group were evaluated for the probiotic load on day 5 and
day 10 of probiotic feeding. We observed a 2-3 log increase in the probiotic supplied
guinea pigs that was maintained across the two time points, suggesting that the probiotics
were able to colonize and persist in the gut (Fig 4-2ab). We found no probiotics in any
extraintestinal tissues. However, both wild type and recombinant probiotics were present
in the intestinal tissues between 104-106 cfu/ml (Figure 4-2c). These data support
probiotic colonization and persistence in the intestines.
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probiotics bacteria colonized the gut, indicating that LAP (from L. monocytogenes or L.
innocua) expressing probiotic prevented L. monocytogenes interaction possibly through
competitive exclusion. Moreover, no Lactobacillus was found in extraintestinal tissues
suggesting that either probiotics expressing Listeria virulence protein not translocate
across the epithelial barrier or if they did translocate they may have been cleared by the
mucosal immune system before interaction with successive tissues.
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4.3.3 Histopathology
No maternal tissues displayed signs of inflammation. The ileum of No Lbc
supplied, control guinea pigs had variable length villi with few lymphocytes, plasma
cells, and resident macrophages in the lamina propria. Lymphocytes and plasma cells also
filled the lamina propria at the base of the mucosa. Goblet cells were mostly confined to
the intestinal crypts. Goblet cells comprised less than 10% of the villous epithelium. No
guinea pigs treated with probiotics and challenged with L. monocytogenes showed any
signs of an increase in inflammatory cells such as heterophils, lymphocytes, and
macrophages. Regardless of the challenge, enterocytes were intact with no necrosis. All
livers had mild numbers of lymphocytes and occasionally plasma cells surrounding the
portal areas of the liver, and was considered background lesion and not related to the
challenge. No lymph nodes had a focal abscess or increased number of heterophils.
Overall, there were no lesions indicating bacterial enteritis or septicemia in any of the
animals.

100
4.3.4 Short chain fatty acid (SCFA) content in guinea pig feces
Here we observed that L. monocytogenes induced a drastic reduction in all SCFAs
in fecal content. Treatment groups supplemented with LbcWT and the recombinant
probiotics helped to rescue the SCFA content. Interestingly, LbcLAPLin showed a 5-fold
increase in butyric acid compared to the No Lbc control. Taken together, these data
suggest that L. monocytogenes has a negative effect on SCFA content and that both
LbcWT and the recombinant probiotics, despite the pregnant background can help to
overcome that negative effect.
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4.3.5 Probiotic modulation of serum cytokines
Probiotics are known to exert modulation over host cytokine secretion and
maintain acute immune homeostasis with regard to commensal intestinal microbiota
through NF-B mediated TNF-a secretion from the host epithelium (Ma et al, 2014;
Pagnini et al 2010). Previously we have observed in in vitro Caco-2 and in vivo healthy
A/J mice that the recombinant probiotics negated Lm induced epithelial secretion of
TNF- and IL-6 (Drolia et al., in preparation; Amalaradjou et al, in preparation). L.
monocytogenes challenged animals that either not fed probiotics or fed WT showed a
significant (p < 0.001) increase in serum IL-6, while recombinant probiotic fed animals
were not significantly (p = 0.2) different from No Lbc control animals. TGF-1 in,
LbcLAPLm and LbcLAPLin supplemented animals were significantly (p < 0.05) lower
then both LbcWT and control challenged animals. TGF-1 has also been shown to be
associated with differentiation of Th17 cells (Eisenstein and Williams 2009). TNF-,
another hallmark inflammatory cytokine showed a similar trend.
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MCP-1 levels were elevated in both the Lm challenge and LbcWT groups, while
the recombinant probiotic fed animals showed levels similar to control. These data
together suggest that recombinant probiotics can either directly or indirectly influence
cytokine production possibly resulting in a decrease in L. monocytogenes induced
intestinal inflammation and help maintain gut immune homeostasis in a pregnant
background.
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4.4

Discussion

L. monocytogenes is an invasive opportunistic intracellular human pathogen. It is
ubiquitous and is transmitted primarily through food resulting in numerous fatal and
costly outbreaks that are associated with consumption of contaminated cheese, ice cream,
smoked fish, ready-to-eat meats, and produce (cantaloupe, apples, spinach) (Marquis et
al. 2016). L. monocytogenes can penetrate the blood-brain and blood-placental barrier,
and as such listeriosis, the disease associated with L. monocytogenes infection typically
manifests as sepsis or meningitis in high-risk individuals (Sacco et al. 2016). Because of
its opportunistic nature, listeriosis is not typically associated with healthy adults, but
rather immune compromised individuals including the very young, elderly, individuals on
immunosuppressive drugs such as cancer patient or organ transplant recipients, HIVAIDS patients and pregnant women (Sleator et al. 2009; Xayarath and Freitag 2012).
Pregnant women exposed to L. monocytogenes typically experience flu-like symptoms;
however, L. monocytogenes associated pregnancy complications include abortion,
stillbirth, premature birth, and infants with L. monocytogenes infections. When L.
monocytogenes breaches the blood-placental barrier and the infant is alive at birth the
child has symptoms of listeriosis at birth and is referred to as early-onset listeriosis;
however, if the infant becomes infected during birth, listeriosis symptoms typically
manifest two weeks after birth and is known as late-onset listeriosis (Bhunia 2008).
According to a global study conducted in 2010, the mortality rate of L.
monocytogenes infection is 22.4% (Kirk et al. 2015). Pregnancy-associated infection
accounts for 17% of total L. monocytogenes infections in the united states and of those
infections 20.3% resulted in fetal loss, 32.9% resulted in infant meningitis, and 36.5%
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resulted in infant sepsis (Jackson et al. 2010). Despite the high mortality rate and
economic healthcare burden of L. monocytogenes infection, there is currently no vaccine
or prophylactic medical intervention for L. monocytogenes. Rather, the CDC outlines a
physical prophylactic intervention by thoroughly cooking all meats, safe food handling,
and avoiding FDA designated high-risk foods including ready-to-eat meats,
unpasteurized dairy products, smoked fish, etc. The development of a preventive
intervention of listeriosis is imminently needed and would have a substantial public
health impact. Probiotics have become an attractive vaccine vector for foodborne
pathogens for several reasons including their ability to persist in the gut, general
promotion of gut health, and they are generally regarded as safe (GRAS) (Amalaradjou
and Bhunia 2012; Sanders et al. 2014). Probiotics produce antibacterial peptides and
macromolecules that negatively impact pathogenic bacteria, while directly and indirectly
modulating host cytokine production to promote overall gut health and homeostasis (Cho
et al. 2014). Lactobacillus casei is a probiotic, lactic acid bacteria that displays many of
these attributes such as persistence in the gut and enhancement of gut barrier integrity
(Amalaradjou and Bhunia 2012). One key drawback is that probiotic health benefits have
been shown to be strain specific and unpredictable and have had limited success
mitigating L. monocytogenes infection (Culligan et al. 2009)
We have shown that LAP is an important L. monocytogenes virulence factor
associated with promotion of paracellular translocation and dissemination of the pathogen
(Burkholder et al. 2010, Drolia et al. In preparation). We have also shown that LAP from
pathogenic L. monocytgenes and non-pathogenic L. innocua are highly homologous.
Moreover, pathogenicity of LAP deficient L. monocytogenes can be rescued by non-
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pathogenic LAP from L. innocua, suggesting that these two proteins may be
interchangeable (Jagadeesan et al. 2010; Jagadeesan et al. 2011). This interchangeability
of LAP and the need for prophylactic listeriosis intervention prompted our lab to develop
a recombinant Lactobacillus casei expressing LAP from either the pathogen (LbcLAPLm)
or non-pathogen (LbcLAPLin). In previous in vitro Caco-2 and in vivo mouse studies, we
found that both recombinant probiotics are equally protective against clinical L.
monocytogenes infection. This inevitably raised the question, are these recombinant
probiotics protective against L. monocytogenes infection in an immunocompromised
model such as pregnancy?
To investigate the protective nature of these Lbc against L. monocytogenes
infection in pregnant individuals an appropriate animal model must be selected. Mice
were adequate in previous studies; however, the differences in placental structure
between humans and mice is too high to make them comparable (Hashino et al. 2015).
Moreover, due to a single amino acid substitution in mice and rats E-cadherin the InlA/Ecadherin interaction does not take place (Lecuit et al. 1999; Lecuit 2007). Guinea pigs
have been used for many years as a pregnant and non-pregnant model for Listeria
pathogenesis (Bakardjiev et al. 2004). Guinea pigs are a InlA permissive species (Lecuit
2007) and are the rodent that shares the most placental similarity with humans,
particularly the barrier and interaction between the dam and fetal tissues during
development (Mess and Carter 2007). Both species have a discoidal placenta;
trophoblasts invade the uterus into the endometrium, and inner third of the myometrium,
and the maternal blood spaces are lined by one layer of trophoblasts during the later
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stages of pregnancy (Leiser and Kaufmann 1994; Disson et al. 2008; Schmidt et al.
2015).
In humans, the fetal gestational period is nine months, with three distinct
development periods divided into three-month long trimesters (Kaur et al. 2007). Due to
increased immune suppression and a thinning of the trophoblast lining of the fetoplacental barrier, L. monocytogenes is most infective during the third trimester of human
pregnancy (Robbins et al. 2010). Pregnant guinea pigs were supplied probiotics for 17
days and challenged with L. monocytogenes during the last 20 days of their 60-day
gestational period (Paavola 1979), the equivalent of the human third trimester. The orally
supplied L. monocytogenes is sufficient for intestinal colonization, but not always clinical
presentation in non-pregnant guinea pigs is 108-1010 cfu/animal (Melton-Witt et al. 2012).
An orally administered dose for 50% fetal infection in pregnant guinea pigs is 104-108
cfu/dam; however, this may not be enough for clinical infection of the dam (Williams et
al. 2011). Pregnant guinea pigs orally dosed with 9  108 or 4.5  109 cfu/animal showed
not physical characteristics of clinical infection in dams; however, challenged control
animals (No Lbc + Lm) showed 100% L. monocytogenes dissemination to the placenta
and 50% dissemination to the fetal liver. These data suggest that, though the dose of L.
monocytogenes administered was not sufficient for clinical listeriosis in the dam, it was
sufficient for fetal infection. Amazingly, these recombinant probiotics reduced
dissemination to extraintestinal tissues like the liver, spleen, and mesenteric lymph node
and completely mitigated dissemination to the lungs and kidney. Recombinant probiotic
supplemented animals did not showed the presence of L. monocytogenes in the placenta
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and fetal liver, while both the No Lbc and LbcWT treated animals 100 and 25% positive,
respectively; however, no fetal brains were positive.
Probiotics are known to induce cytokine production to reduce inflammation and
maintain gut homeostasis (Ng et al. 2009). Pro-inflammatory cytokine IL-6 is an
essential regulatory protein for acute inflammation. It is responsible for recruitment of
monocytes and neutrophils post L. monocytogenes infection (Scheller et al. 2011) and has
recently been linked to differentiation of CD4+ T cells to primary pro-inflammatory Th17
cells (Bettelli et al. 2006; Simone et al. 2015). Additionally, TGF-1 has also been
shown to be associated with differentiation of Th17 cells (Eisenstein et al. 2009; Li et al.
2006). We have previously shown in non-pregnant mice that through activation of NFB, both intestinal and sera levels of TNF- and IL-6 were increased during L.
monocytogenes infection resulting in destabilization of the epithelial barrier and increased
extraintestinal translocation of L. monocytogenes; however, supplementation of
LbcLAPLm and LbcLAPLin decreased L. monocytogenes induced TNF- and IL-6. Here
we observed the same trend in our pregnant guinea pig model, and showed that serum
TNF- and IL-6, as well as TGF-1 levels, are reduced by the supplementation of
recombinant probiotics. This suggests that the recombinant probiotics both help maintain
gut homeostasis and mitigate L. monocytogenes induced cytokine stimulation; however, it
is unclear if the probiotic regulation of cytokines is direct, resulting from interaction with
host epithelial cells or indirect, resulting from the production of a metabolite such as
SCFA which interacts with host cells. It is important to note that the reduction in
proinflammatory cytokines could simply be a result of less interaction and invasion of
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host epithelial or immune cells by L. monocytogenes. We suppose that it is a
combination of the three.
Short chain fatty acids (SCFAs; acetic, propionic and butyric acids) are known to
enhance the intestinal epithelial integrity and overall gut health through maintenance of
tight junction proteins (Elamin et al. 2013) and regulation of inflammation (Blaise et al.
2007; Nancey et al. 2002; Tremaroli and Backhed 2012). Moreover, in addition to their
positive gastrointestinal health benefits, they are also able to negatively impact L.
monocytogenes. Butyrate has been shown to affect both membrane composition and
rigidity (Jolatok et al. 2010) and virulence gene transcription (Sun et al. 2012), while
acetate, butyrate, and especially propionate can inhibit L. monocytogenes growth
(Joloyok et al. 2010; Menconi et al. 2013). Also, SCFAs have been shown to induce host
epithelial cells to secrete antimicrobial peptides, such as bacteriocins (Amalaradjou and
Bhunia 2012), which can also inhibit luminal pathogens. In our previous study, we
determined that L. monocytogenes were able to negativly impact SCFA synthesis
significantly in healthy A/J mice. While the probiotics were not able to enhance overall
SCFA synthesis compared to the control. LbcWT, LbcLAPLm, and LbcLAPLin were able
to mitigate the adverse effect of L. monocytogenes (Amalaradjou et al In Preparation).
Here we have shown that both wild type and recombinant probiotics protect the host
against L. monocytogenes inhibition of SCFA production in the gastrointestinal tract and
this may serve as an important factor in the reduction of pathogen extraintestinal and fetal
dissemination in pregnant hosts. Moreover, we have shown that the supplementation of
probiotics has general health benefits like the reduction of total serum cholesterol, which
could serve to protect the host against heart disease and heart attack.
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In summary, we have shown that recombinant LAP expressing probiotics protect
against extraintestinal dissemination to both the dam and the fetus, decreased proinflammatory cytokines, decreased L. monocytogenes mediated adverse SCFA effect, and
positively influenced general health. Importantly, we showed that the recombinant
probiotic expressing non-pathogenic LAP was just as affective at these attributes and
more effective at lowering serum cholesterol, negating the need to use any pathogenic
factors and providing a “feel good” factor to potential consumers that a product
containing a pathogenic virulence factor cannot. This probiotic vaccine could potentially
provide much needed protection and relief to high-risk groups, including pregnant
women and their fetuses against listeriosis. Moreover, this research suggests an exciting
platform for possible prevention of many other foodborne pathogens, such as diarrheal
disease-causing pathogens like Salmonella, which is of grave concern in the developing
world.
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Appendix A: Purification of recombinant GAPDH

Introduction
Within the research done in this thesis purified Listeria adhesion protein (LAP) and
glyceraldehyde phosphate dehydrogenase (GAPDH).

Methods
Bacterial Strains and Growth Conditions
E. coli BL21 secreting His-tagged GAPDH (clones 1-10) were grown in 500 ml of LuriaBertani broth (LB, 0.5% NaCl, 1% tryptone peptone, and 0.5% yeast extract) containing
ampicillin (100 μg/ml) at 37°C for 3 h and transferred to room temperature and grown
for 13-15 h. Cultures were shaken (120 rpm/min) during the entire 16-18 h of growth.

Selection of E. coli BL21 secreting His-tagged GAPDH clone
Each clone was grown by the conditions stated above. Bacterial cells were pelleted by
centrifugation at 6,000 xg for 10 min at 4oC. Cells were washed with sterile PBS and
pelleted by centrifugation again at 6,000 xg for 10 min at 4oC. Washed cells were
suspended in cell 2X sample solvent (0.5 M Tris-Hcl, pH 6.8 4% SDS, 0.3 M mercaptoethanol) and sonicated on ice for 3 cycles of 15 s sonication and 15 s rest. Pellet
cell debris by centrifugation at 8000 xg for 3 min. Protein containing supernatant sample
was retained and quantified using BCA kit (Thermo Scientific). 10 μl of bromophenol
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pump. Beads were equilibrated with 30 ml (6 bead volumes) binding buffer supplied in
His Binding Kit (5 ml/min). Sample (40 ml) was applied to the column at 0.5 ml/min.
Binding buffer supplied in His Binding Kit (30 ml) was applied to the column (0.5
ml/min) after sample was applied. Beads were washed with 30 ml of wash buffer
supplied in His Binding Kit (5 ml/min). Bound His-tagged proteins were eluted from the
column by adding 30 ml of elution buffer supplied in His Binding Kit at 0.5 ml/min,
while collecting 0.5 ml fractions. Protein content of each collected fraction was
quantified by NanoDrop 1000 (Wilmington, DE) and fractions containing proteins were
pooled.

Desalting with HiTrap Desalting column and Protein Storage
Pooled fractions were applied to a 5 ml HiTrap Desalting column (GE) in 5 ml fractions.
Proteins were desalted and eluted by adding sterile PBS to the column 0.5 ml/min) while
0.5 ml fractions were collected. Proteins were eluted until fractions containing no protein
are collected. Protein quantified by NanoDrop 1000. Desalted proteins were stored in
100 μl aliquots at -80oC until use.
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Appendix B. Interaction between rLAP and rGAPDH using an overlay assay

Introduction
The Listeria Adhesion Protein (LAP: 104 kDa) has been identified as a noncanonical L.
monocytogenes virulence factor. LAP is a bacterial bifunctional alcohol acetaldehyde
dehydrogenase (Aad) enzyme encoded by lmo 1634 gene that can be identified
intracellularly, in the cell wall, and is secreted from L. monocytogenes (Kim et al. 2006).
Cytoplasmically, LAP is a housekeeping enzyme participating in the anaerobic glycolytic
process which also acts as an adhesion factor in L. monocytogenes. By comparing LAP
amino acid sequence with existing protein databases, LAP was identified as a bifunctional enzyme which consists of an N terminal NAD dependent aldehyde
dehydorgenase (ALDH) and a C terminal alcohol dehydrogenase (ADH) domain
(Jagadeesan et al. 2010). LAP also moonlights as an extracellular adhesion protein that
interacts with host intestinal Hsp60 (Wampler et al. 2004). LAP is secreted through the
alternate secretory pathway SecA2 and re-associates with the bacterial cell through a
mechanism currently being elucidated (Burkholder et al. 2010). It has been postulated
that LAP possibly binds to cell wall expressed glyceraldehyde dehydrogenase (GAPDH)
(unpublished). To investigate this an overlay assay was performed.

Materials and Methods
Overlay Assay. Recombinant GAPDH (rGAPDH) and LAP were nickel column purified
(see Appendix A for method) and separated using SDS-PAGE (7.5% acrylamide).
Protein was transferred to a hydrophobic membrane. rGAPDH lanes were excised from
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the membrane and allowed to interact with rLAP (10 μg/ml) in PBS for 12 h at 4oC.
Membrane was washed using sterile PBS-T (0.1% Tween-20) and immunoprobed with
anti-LAP mAb (0.5 μg/ml) for 2.5 h at room temperature with gentle agitation.
Membrane was washed and probed with secondary HRP conjugated anti-mouse Ab
(0.25 μg/ml) for 1h. with at room temperature with gentle agitation. Blot was developed
using chemiluminescent substrate (cell signaling) and visualized on film. Controls were
used to establish that the anti-LAP mAb has no affinity for rGAPDH, while having
affinity for rLAP.

Results and discussion
We observe that there was interaction between rGAPDH and rLAP in the overlay assay.
Banding can be seen at 64 kDa using the anti-LAP antibody suggesting that rLAP bound
to rGAPDH on the membrane. It was clearly seen that anti-LAP mAb does not interact
with rGAPDH, while showing strong interaction with rLAP. These data suggest that a
possible candidate for the LAP cell wall anchor protein is cell wall expressed GAPDH.

145
Appendix C. Anti-GAPDH antibody has no affinity for native GAPDH

Materials and method
Total protein extraction from L. monocytogenes and L. innocua
Listeria cultures were grown in Tryptic soy broth containing 0.6% yeast extract (TSBYE)
for 16-18 h at 37oC shaking.

Bacterial cells were pelleted by centrifugation at 6,000 xg

for 10 min at 4oC. Cells were washed with sterile PBS and pelleted by centrifugation
again at 6,000 xg for 10 min at 4oC. Washed cells were resuspended in cell 2X sample
solvent (0.5 M Tris-Hcl, pH 6.8 4% SDS, 0.3 M -mercaptoethanol)and sonicated on ice
for 3 cycles of 15 s sonication and 15 s rest. Pellet cell debris by centrifugation at 8000
xg for 3 min. Protein containing supernatant sample was retained and quantified using a
BCA kit (Thermo Scientific).

Western Blot
L. monocytogenes and L. innocua total protein (25 μg/well) and rGAPDH (5 μg/well)
were separated by SDS-PAGE and transferred to a hydrophobic membrane. Membrane
was immunoprobed by anti-GAPDH pAb (1 or 2 μg /ml). A secondary HRP conjugated
anti-mouse Ab was used. Bands were developed using chemiluminescent substrate (Cell
Signaling) and developed on film

Results
The anti-GAPDH antibody showed no affinity to native GAPDH from L. monocytogenes
or L. innocua.
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Appendix D. Development of polyclonal antibody to L. monocytogenes GAPDH

Introduction
Anti-GAPDH antibody that was developed by a previous lab member only shows affinity
for the recombinant GAPDH that it was developed from; however; it has no affinity for
native GAPDH from Listeria. For further analysis of GAPDH as a candidate cell wall
anchor for LAP an antibody must be developed that has affinity for both native and
recombinant GAPDH from L. monocytogenes. Here we show the development of this
antibody.

Materials and Methods
Total protein extraction
Listeria monocytogenes F4244 culture were grown in Tryptic soy broth containing 0.6%
yeast extract (TSBYE) for 16-18 h at 37oC shaking.

Bacterial cells were pelleted by

centrifugation at 6,000 xg for 10 min at 4oC. Cells were washed with sterile PBS and
pelleted by centrifugation again at 6,000 xg for 10 min at 4oC. Washed cells were
resusdpended in cell 2X sample solvent (0.5 M Tris-Hcl, pH 6.8 4% SDS, 0.3 M mercaptoethanol) and sonicated on ice for 3 cycles of 15 s sonication and 15 s rest. Pellet
cell debris by centrifugation at 8000 xg for 3 min. Protein containing supernatant sample
was retained and quantified using a BCA kit (Thermo Scientific).
Western blot showing affinity of anti-GAPDH antibody L. monocytogenes total protein
(25 μg/well), intracellular fraction (25 μg/well), cell wall fraction (25 μg/well), and
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Appendix G. Fecal DNA extraction and 16S rRNA amplification for microbiome

Extraction of DNA from feces for microbiome analysis
Fecal DNA was extracted using a MP Biomedicals FastDNA Spin Kit for Soil (Cat. No.
116560200, Santa Ana, CA) following the manufacturer’s instructions. Briefly, 50 mg of frozen
feces was applied to a Lysing matrix E tube from each mouse and 978 μl of sodium phosphate
buffer was added. Feces was disrupted using a MP Biomedical FastPrep bead beater (Santa Ana,
CA) at speed 5.5 for 30 s. Fecal debris was pelleted by centrifugation at 14,000 rpm for 5 min.
Supernatant was transferred to a clean 1.5 ml microcentrifuge tube and 250 μl of protein
precipitation solution (PPS) was added. Tubes were inverted 30 times to mix. Precipitated
protein was pelleted by centrifugation at 14,000 rpm for 5 min. Supernatant was transferred to a
clean 2 ml tube. Mix Binding Matrix (900 μl) was added to the supernatant and thoroughly
mixed by inverting for 2 min by hand. Mix was incubated for 3 min at room temperature. All
beads that settled were resuspended by inversion. Mix was added 600 μl at a time to the Spin
Column and centrifuged for at 14,000 rpm for 1 min until samples were fully processed through
the Spin Column. DNA bound to the matrix of the spin column was washed twice with 500 μl of
SEWS buffer. SEWS buffer was pulled through the matrix by centrifugation at 14,000 rpm for 1
min. Tubes were centrifuged for an additional 2 min at 14,000 rpm to ensure all SEWS buffer
was removed. DNA was eluted from the SPIN column to a clean capture tube by passing 50 μl
of DES solution through the Spin Column by centrifugation at 14,000 rpm for 2 min. All DNA
was quantified using a NanoDrop 1000 (Wilmington, DE) and stored in -20oC.
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16S rRNA PCR of mouse fecal DNA for Microbiome Analysis
Primary PCR master mix was prepared mixing the items in the table 3-X with template
DNA in a 96 well PCR plate. 16S rRNA was amplified between variable regions 3 and 4. The
Primers used were:
Forward: 5’-TCTTTCCCTACACGACGCTCTTCCGATCTNNNNTACGGRAGGCAGCAG-3’
Reverse: 5’GTGACTGGAGTTCAGACGTGTGCTCTTCCGATctCTACCRGGGTATCTAATCC-3’

Table F-1. 16S Primary PCR Master Mix
Reagent
Stock Concentration
PCR Water
---BSA
2%
Q5 Master Mix 2X
F Primer
25 μM
R Primer
25 μM
DNA Template 5 ng/μl
Total vol.

Vol./ reaction (μl)
21.25
1.25
25.00
0.75
0.75
1.00
50.00

Vol./ 96 well plate (μl)
2125
125
2500
75
75
Do Not Add
4900

PCR was run using conditions in Table F-2.
Table F-2. Primary PCR conditions
Temperature (oC)
Initial Denaturation
95
Cycles
Denaturation
94
Annealing
58
Extension
72
Final Extension
72

Time

Cycles
5 min
30 s
20 s
20 s
10 min

1
15

1

Axygen AxyPrep Mag PCR product clean-up
PCR products from primary PCR were centrifuged at 1000 xg for 1 min. Using a
multichannel pipette, 90 μl of Axygen AxyPrep Mag (Cat. No. 14-223-152, Fisher Scientific)
beads was added to each well. Samples were mixed by pipetting for 10 min. and incubated at
room temperature for 5 min. Beads were separated by placing 96 well PCR-plate on SPRI
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magnet for 2 min. Supernatant was removed by pipetting while leaving the plate on the magnet.
Beads were washed twice with 200 μl of 70% ethanol to each well and air dried for 15 min.
DNA was suspended in 30 μl of PCR grade water.
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